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ABSTRACT 
 
Epidemiological studies suggest pre-menopausal women have a reduced risk for 
sporadic and inflammation-associated colon cancer compared to post-menopausal 
women and men. The studies presented herein aim to determine the protective 
mechanisms of estradiol (E2) during sporadic and inflammation-associated colonic 
carcinogenesis. 
When investigating the role of E2 and fish oil at the earliest stage of sporadic 
colon cancer development, E2 had no effect on DNA adduct formation while dietary fish 
oil significantly reduced DNA adduct formation.  Contrarily, E2 significantly induced 
apoptosis of damaged colonocytes while fish oil was not protective.  
In an in vivo model of inflammation-associated colon carcinogenesis with E2 
administered following induction of DNA damage and initiation of inflammation, E2 
treatment was associated with decreased colon tumor size and number in wild type (WT) 
but not estrogen receptor (ER) β knockout (ERβKO) mice. Interestingly, apoptosis was 
reduced and proliferation increased by E2 in these tumors in WT mice.  This may be due 
to the altered ER expression in these tissues as the tumors developed, with ERβ 
expression decreasing concomitantly with ERα expression increasing.  
Contrary to the protective effect of E2 on inflammation-associated colon tumor 
formation, which was dependent on ERβ, during acute inflammation in the colon E2 was 
protective against inflammation in both WT and ERβKO mice and injury in ERβKO 
mice.  The protection against inflammation is likely due to the reduction of pro-
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inflammatory cytokine expression by E2. Apoptosis and proliferation were decreased and 
increased in the proximal and distal colon respectively in ERβKO mice. 
In vitro studies further elucidated the roles of ERα and ERβ in colonocytes.  E2 
and ERβ, but not ERα, specific agonists reduced cell number and induce apoptosis in 
nonmalignant colonocytes. This effect was lost in the presence of mutated p53. In ERα 
overexpressed nonmalignant colonocytes, E2 had no effect on cell number while ERβ 
agonist and ERα agonists decreased and increased cell number respectively. 
These studies suggest that E2 is protective in the colon and ERβ is required for 
protection against carcinogenesis but not protection against inflammation.  Additionally, 
the protection against colon carcinogenesis is likely p53 mediated.    
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Colon Cancer Statistics, Pathogenesis and Risk Factors 
In the United States, colon cancer is the third leading cause of cancer related 
deaths in men and women, falling behind lung cancer and prostate or breast cancer in 
men and women respectively [1].  Fortunately, however, in recent years the number of 
colon cancer cases has actually decreased [2].  This is due, in part, to improved 
knowledge of preventative measures and better methods of early detection.  Despite this, 
the fact remains that over 50,000 people are expected to die from colon cancer in the 
United States in 2013. 
Development of colon tumors is a time intensive process, oftentimes requiring 
anywhere from 10 to 15 years for tumors to form [3]. Colon cancer pathogenesis occurs 
in three primary physiological steps: initiation, promotion, and progression.  Initiation is 
characterized by damage to the DNA resulting in the dysregulation of normal gene 
functions.  These mutations can be the result of several factors including genetics, 
lifestyle, and diet.  An indicator of impending DNA damage that occurs during colon 
carcinogenesis but is primarily measured in experimental models is DNA adducts.  DNA 
adducts are formed when carcinogens covalently bind to DNA.  With the carcinogen 
bound, DNA replication cannot proceed normally and errors are incorporated into the 
daughter strands unless DNA repair mechanisms correct the error.     
 2 
 
One gene often affected during the initiation phase of colon carcinogenesis is the 
adenomatous polyposis coli gene (APC) [4]. Dysregulation of APC in turn is known to 
cause over expression of mutant β-catenin and can lead to mutations in the proto-
oncogene k-ras [5, 6].  The physiological results of the mutations to these genes are 
decreased apoptosis and increased proliferation of the affected cells [5-7].  In healthy 
colon tissue, proliferation is confined to the base of colonic crypts with cells migrating 
up towards the lumen as they differentiate and eventually sloughing off; a process which 
takes between 4-6 days [8].  As cells lose the ability to properly regulate proliferation, 
the proliferative zone expands and S-phase cells can be found throughout the entire 
height of the crypt [9].  
The second phase of colon cancer development, promotion, is hallmarked by the 
formation of polyps. Adenomas, one classification of polyp, are most likely to become 
cancerous.  Adenomas are relatively common and it is estimated that between one third 
to one half of the population will develop at least one adenoma within their lifetime [10, 
11]. Fortunately, less than 10% of adenomas develop into adenocarcinomas [12].  
Further mutations to oncogenes and tumor suppressor genes accumulate in affected cells, 
in part because the first mutation makes it easier for subsequent mutations to occur.  
Some of the most commonly altered genes in colon tumors include APC and k-ras, as 
previously mentioned, as well as p53, deleted in colorectal carcinoma (DCC), and Dpc4 
[7, 13-15].  
Ultimately, adenocarcinomas can infiltrate through the lining of the colon, invade 
into neighboring tissues, and cancer cells can metastasize to distant locations. Each of 
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these occurrences is part of the third phase of colon carcinogenesis, progression.  Here, 
cancerous cell growth outpaces healthy cell growth and the tumor has acquired several 
mutations leading to increased angiogenesis, dysregulated proliferation and resistance to 
apoptosis.  
Clinically, there are five categories of colon cancer development, ranging from 0 
to 4.  Stage 0 is alternatively referred to as carcinoma in situ. At this stage, the 
developing tumor remains contained within the lining of the colon.  In Stage 1, the tumor 
has penetrated through several layers of the colon, but has not spread beyond the muscle 
layer.  Once the tumor has breached the muscle layer but has not infiltrated into the 
lymph system it has developed into a Stage 2 malignancy.  Stage 3 has entered the 
lymph nodes but not metastasized to distant organs, which happens in Stage 4.  Stages 0 
and 1 are often treated by simple removal of the affected tissue.  For Stages 2 and 3, 
surgical removal of the tumor is often accompanied with chemotherapy.  Once Stage 4 
colon cancer has been reached, surgical colon tumor removal is aimed more at relieving 
symptoms or preventing further complications associated with the disease as depending 
on the extent of the metastasis, it may be impossible to fully extract the cancerous tissue.  
Here again, chemotherapy or radiation therapy may be used, as a method to relieve the 
patients symptoms. 
There are several risk factors for developing colon cancer, among them being age 
with persons over 50 years being at a significantly higher risk.  Genetics can also play a 
large role. The two most common genetic disorders resulting in colon tumor 
development are familial adenomatous polyposis (FAP) and Lynch Syndrome, together 
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accounting for between 4-6% of all colon cancers [16, 17]. FAP is caused by inherited 
mutations to APC resulting in the formation of hundreds of polyps and persons with this 
disease often develop cancer by the time they are 20 years of age. Most persons with 
FAP undergo colonectomies to treat their condition. Persons with Lynch Syndrome do 
not develop near as many polyps however they have an 80% overall lifetime risk for 
developing colon tumors. This condition is due to mutations in several different genes 
that regulate DNA repair. 
In addition to age and genetics, lifestyle and diet are large contributing factors for 
colon carcinogenesis.  Studies have shown that persons with higher BMIs and sedentary 
habits are at a significantly increased risk for colon tumor formation [18].   In regards to 
diet, several components have been demonstrated to both increase and decrease colon 
cancer risk depending on quantity and frequency of consumption.  Among the foods 
known to increase cancer risk are: processed meat, red meat, foods high in saturated 
fatty acids, highly refined grains and starches, excessive alcohol and added sugar [19-
22].  Proposed mechanisms behind the increased risk include altering the membrane of 
epithelial colonocytes and increasing insulin and insulin-like growth factor-1, each of 
which can result in increased proliferation in cells [20, 23-25].  On the other end, 
consumption of whole grains, fruits and vegetables, dietary fiber, tea, soy and fish rich in 
n-3 polyunsaturated fatty acids are all tied to a reduced risk [26-33].  In general, these 
beneficial compounds act as chemopreventatives and protect the tissue from developing 
tumors. 
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Screening for colon cancer is advised once a person reaches 50 years via a 
colonoscopy with subsequent colonoscopies every ten years.  Persons who have family 
history of colon cancer or who are otherwise known to be at an increased risk are 
suggested to be screened earlier and more frequently [34]. Detection of colon cancer is 
relatively easy with regular screening, and when caught and treated early enough, the 
five year survival rate is around 90%.  Unfortunately, only four out of every ten people 
with colon cancer have their cancer detected at this early stage due to the fact that they 
are not getting themselves tested for the disease [1].  This is due, in part, to limited 
accessibility and affordability of the procedure.  
The financial burden of having and treating colon cancer has been steadily 
increasing over the past few decades.  By 2020, it is predicted that medical care 
expenditures in the United States for colon cancer will increase over 40% to $14.02 
billion [35].  Costs for each individual inpatient rose 37.6% from 1998 to 2007 [36].  
Fortunately, it is suggested that if people were to make moderate changes to their diet 
and lifestyle, reducing habits that promote cancer growth and increasing activity and 
consumption of beneficial dietary components, then up to 70% of the current costs 
associated with colon cancer could be prevented [37, 38].   For colon cancer, 
chemopreventative strategies are not only fiscally beneficial but could lead to the 
prevention of colon cancer related deaths in numerous people. 
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Fish Oil and Colon Cancer 
 Epidemiological studies show that populations with diets high in fatty fish, and 
subsequently fish oil, are at a reduced risk for developing colon cancer [39].  Fish oil is 
available as fish oil capsules or directly from consumption of fatty fish.  Fatty fish and 
fish oil capsules contain the n-3 polyunsaturated fatty acids (PUFA) docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA).  DHA is a 22 carbon fatty acid with six 
double bonds while EPA has 20 carbons and five double bonds (Figure 1.1). Both of 
these n-3 fatty acids can also be synthesized from the essential fatty acid, α-linolenic 
acid, through elongation and desaturation of the carbon-carbon bonds. This conversion, 
however, is much less efficient than absorbing the compounds directly from the diet.  
Fish high in DHA and EPA content include salmon, tuna, and swordfish.  Farm raised 
fish have low levels of the n-3 PUFAs compared to wild caught fish due to the fact that 
the fatty acids are not produced by the fish themselves but rather are obtained through 
the fish’s diet of algae.   
 
Figure 1.1.  Structures of the n-3 PUFAs, DHA and EPA. 
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 There are several proposed mechanisms by which fish oil is suggested to prevent 
colon cancer.  DHA has been shown to initiate cell cycle arrest and induce apoptosis 
[40].  In LS-174T cells, a human colon tumor cell line, treatment with DHA reduced 
proliferation and suppressed prostaglandin E2 (PGE2) and cyclooxygenase-2 (Cox-2) 
induced by arachidonic acid [41].  Aberrant Cox-2 expression is an indicator of colon 
tumor invasion and metastasis and in turn leads to overexpression of PGE2 which also 
promotes cancer cell growth [42].  In addition to affecting Cox-2 and PGE2, DHA is 
known to upregulate the phosphatidylinositide 3-kinase (PI3K) and mitogen-activated 
protein kinase (MAPK) signaling pathways, both of which are often involved in 
inducing apoptosis [43].   
 Epidemiological studies investigating EPA have found that in persons with FAP, 
EPA consumption significantly reduced the size and number of polyps [44].  For this 
PUFA, studies suggest that suppression of angiogenesis may be a mechanism of action 
[45].  Other studies have found that dietary EPA in APCmin/+ mice significantly 
reduced intestinal cell proliferation and suppressed Cox-2 expression and inhibited 
nuclear translocation of β-catenin [46].  
 As a whole, dietary fish oil has been demonstrated in vivo to reduce the 
formation of azoxymethane (AOM) induced DNA adducts [47-49].  Combinatory fish 
oil and pectin (a soluble fiber) diets in mice have repeatedly proved successful at 
preventing early markers of colon carcinogenesis as well as colon tumor formation itself 
[47-51].  Induction of apoptosis is consistently demonstrated as a mechanism of action 
via modulation of several pro and anti-apoptotic proteins including B-cell lymphoma 2 
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(Bcl-2), peroxisome proliferator-activated receptor delta (PPARdelta), PGE2 and 
prostaglandin E3 (PGE3) [52, 53].  
 
Estrogen and Colon Cancer 
 
Estrogens are  the primary sex hormones in females. Biosynthesis of estrogens in 
women principally occurs in the ovaries or, during pregnancy, is produced by the 
placenta.  Aromatase activity in adipocytes can also convert testosterone into estrogen.  
De novo synthesis of estrogen begins with cholesterol which through a series of 
reactions and multiple interconnected pathways is converted into one of the three kinds 
of estrogen [54]. 
 
Figure 1.2.  Skeletal structures of the three natural forms of estrogen: 17β-estradiol, 
estriol, and estrone. 
 
   The three naturally occurring forms in most animals are: estrone, estriol, and 
17β-estradiol (E2) with E2 being the predominant active form (Figure 1.2). Estrogens are 
required for the development of secondary sex characteristics in women and are an 
 9 
 
integral part of the female reproductive system [55].  Additionally, estrogens have been 
demonstrated to have important functions in bone, brain, adipose, and cardiovascular 
tissues as well as in the male reproductive system [56, 57].        
Post-menopausal women receiving hormone replacement therapy (HRT) or 
estrogen replacement therapy (ERT) are at a reduced risk for the disease compared to 
post-menopausal women not on HRT or ERT [58-62].  The protection observed in the 
post-menopausal women was lost however, if they discontinued using the therapies.  In 
vivo studies investigating the function of estrogens during colon carcinogenesis have 
demonstrated that treatment with E2 and metabolic precursors to E2 reduces the 
formation of colon tumors and of aberrant crypt foci (ACF), which are early markers of 
colon tumorgenesis [63-65].  These data suggest that estrogen may play a role in 
preventing colon cancer. 
The evidence for E2 being a true chemopreventative compound and not an 
effective treatment for pre-existing colon tumors comes primarily from in vitro 
experiments using colon tumor cell lines.  While there is some conflicting data, in most 
cases in malignantly transformed cell lines E2 has no physiological effect [66-68].  
Contrarily, in Young Adult Mouse Colonocytes (YAMC), a non-malignant colon cell 
line, E2 treatment results in a decrease in cell number [63].  These data point to the idea 
that the window for opportunity for effective treatment with E2 in colon cancer is prior to 
tumor formation. 
The mechanisms behind this observed protection both in vivo and in vitro is 
proposed to be through the modulation of apoptosis.  In vitro, E2 treatment in YAMCs 
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has been shown to upregulate apoptosis, in part through a p53 mediated pathway [69].  
p53 is an important tumor suppressor gene that is found to be altered in over 50% of all 
cancers due to mutations that are thought to occur later during colon tumorgenesis.  In a 
normally functioning cell, p53 expression is induced in response to DNA damage or 
other forms of cellular stress.  Subsequently, p53 initiates cell cycle arrest and apoptosis.  
This protects the cell from accumulating multiple mutations and becoming cancerous.  
Direct mutation of p53 is not the only way that p53 can be dysregulated; oncogenic 
transformation of other proteins within the p53 pathway, such as murine double minute 2 
(Mdm2) [70].   Dysregulated Mdm2 results in rapid degradation of p53, reducing the 
cell’s ability to initiate apoptosis. Weige et al. demonstrated that while E2 reduced cell 
number and induced apoptosis in YAMCs, this effect was lost in YAMC mp53/neo cells, 
a homologous cell line containing a p53175H mutant gene [69].  This demonstrates that 
functional p53 is required for the protective effect of E2.  
Other in vitro studies have found that E2 suppresses activation of protein kinase 
B (AKT) and extracellular-signal-regulated kinase 1/2 (ERK1/2) resulting in suppression 
of PGE2 and Cox-2 [71].  AKT is a protein whose overexpression often occurs early on 
during colon carcinogenesis.  This overexpression causes inactivation of Mdm2 which in 
turn decreases p53 resulting in reduced apoptosis of cells.   ERK1/2 on the other hand 
initiates cell cycle progression and proliferation. Overexpression of either protein results 
in uncontrolled growth of cells and promotes tumor formation.   
In vivo experiments corroborate in vitro data.  Apoptosis has been demonstrated 
to be upregulated by E2 at the ACF stage in an AOM induced model of colon 
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carcinogenesis [63].  A separate study investigating the effect of E2 on ACF formation in 
mice heterozygous for p53 observed that the protective effect of E2 was partially lost 
compared to wild type (WT) mice, further demonstrating the interplay between E2 and 
p53 (Weige, data not published). Interestingly, apoptosis has also been observed to be 
upregulated in healthy animals not subjected to carcinogen [72, 73].  It is important to 
note that the increase in apoptosis in these animals was minimal (less than 0.1%) and 
was not visibly disruptive of healthy tissue physiology. This fact again supports the 
chemoprotective role of E2 in the colon.        
 
Estrogen Receptors  
The effects of E2 in the body are instigated by the binding of ligands to the 
nuclear receptors known as estrogen receptors (ER).  There are two primary subtypes of 
ER, ERα and ERβ, which in general have physiologically opposite effects on tissues and 
systems.  ERα is known to initiate proliferation and is associated with increased cancer 
growth in the tissues where it is the predominate ER, such as in the breast [74, 75]. ERβ 
on the other hand is associated with decreased growth, increased apoptosis and cell cycle 
arrest. These ERs are expressed throughout the body in numerous tissues.  ER 
expression of one subtype or the other is not mutually exclusive and both receptors can 
be present in the same tissue, despite their opposite actions [76].   
Activation of the ERs elicits downstream effects in one of several ways.  The 
primary method starts when a ligand binds to the ER on the nuclear membrane.  The 
receptors then dimerize and translocate into the nucleus where they bind to estrogen 
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response elements (ERE) found in the promoter region of target genes.  Once bound, 
activation of the ERE causes the recruitment of additional proteins to the promoter 
region that will either result in the increase (co-activators) or decrease (co-repressors) 
expression of the target gene mRNA and protein culminating in a physiological 
response.   
A secondary method by which ERs regulate transcription is called transcriptional 
cross talk and does not involve direct binding to DNA.  Instead, this mechanism relies on 
the interaction of ERs at activator protein-1 (AP-1) binding sites with Fos and Jun 
proteins.  The ER-AP-1 complex binds p160 co-activators via ER activation function 
domains on the ER and together this stabilizes protein complexes containing c-Jun and 
transcriptional co-activators at the promoter of the target genes [77].  Some genes that 
are regulated using this mechanism include cyclin D1 and insulin-like growth factor 1 
[78, 79]. ERs can also activate genes that have promoter regions rich in GC content in a 
similar manner by interacting with the Sp1 transcription factor [77].     
In addition to genomic actions of ERs, there is evidence that ER activation at the 
plasma membrane, as opposed to the nuclear membrane, can elicit more rabid responses 
in cells not relying on RNA and protein production.  Here, it is suggested that ERs 
congregate in caveolae of endothelial cells and upon ligand binding can activate 
endothelial nitric oxide synthase through protein kinase phosphorylation [80].  
Alternatively, ligand-bound plasma membrane ERs may also activate tyrosine kinase 
receptors including IGF-1, epidermal growth factor receptor (EGFR), and human 
epidermal growth factor receptor 2 (HER2) [81-83]. 
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ERα is the predominant ER in reproductive tissues including breast, endometrial, 
ovarian and hypothalamic tissue.  It is encoded for on chromosome 6 in the human 
genome. Conversely, ERβ is located primarily in heart, endothelial, bone, kidney, lungs, 
brain, and intestinal cells and is encoded for on chromosome 14.  Both ERs are 
composed of three principal domains: the N-terminus domain, the DNA-binding domain 
and the ligand-binding domain.  Activation function (AF) domains are located within the 
N-terminus domain and the ligand-binding domain.  AF domains are requisite for 
regulation of the transcription activities of the ERs and are sites for cofactor binding and 
dimerization upon activation of the ER.  Between ERα and ERβ, the DNA-binding 
domain has the highest homology at over 95%.  The ligand-binding domain shares 
around 55% homology and the N-terminus domain only has about 15% homology 
between the ER subtypes.    In addition to the poor sequence homology of the N-
terminus domain, it is also significantly shorter in ERβ compared to ERα  (Figure 1.3)  
[84].  The physiologically different effects between ERα and ERβ are thought to arise 
from the disparate amino acid sequences comprising the AF2 domain within the ligand 
binding domain.  
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Figure 1.3.  Comparative diagram of the differences in structural domains between ERα 
and ERβ. Adapted from Koehler et al. [85]. 
 
 
In the colon, ERβ is the primary ER and scientific evidence points to this ER 
being the receptor through which E2 exerts its protective effect.  Oral estrone was 
equally effective at reducing AOM induced tumor multiplicity in ERα WT and ERα 
knockout (KO) mice, ruling out ERα as the mediator of estrogenic effects in the colon 
[64].  In experiments conducted in ERβKO, however, E2 treatment had no effect on ACF 
formation or on induction of apoptosis. In contrast, WT mice from the same study had 
reduced ACF formation and an induction of apoptosis in the presence of E2 [63]. 
Additionally, treatment with ERβ specific agonists in ovariectomized rats also induced 
apoptosis of colonocytes [86].  
Both epidemiological studies and experimental models have demonstrated that as 
colon tumors develop, the expression of ERβ in colonocytes decreases [87, 88].  This 
loss of ERβ may be the reason that malignantly transformed cells are no longer 
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responsive to treatment with E2.  In humans, it was observed that colon tumors not 
expressing ERβ were more likely to be at a higher stage of cancer and that persons with 
these tumors were at a higher risk for death compared to those with colon tumors 
expressing ERβ  [89].   These data highlight the importance of ERβ during colon 
carcinogenesis.             
 
Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a collection of diseases affecting the small 
intestine and the colon. The two main conditions associated with IBD are Crohn’s 
Disease and ulcerative colitis.  Common symptoms of IBD include fever, diarrhea, rectal 
bleeding, and weight loss [90].  These symptoms come and go at varying levels of 
severity.  In the United States, over one million people are currently diagnosed with 
IBD.   Most commonly, IBD occurs in persons in their twenties and thirties with a 
second peak of flare-ups in the same persons later in life.  Both forms of IBD occur due 
to aberrant immunological responses to antigens in normally occurring proteins in 
genetically susceptible hosts.  This results in disruption of intestinal membrane function, 
creating large gaps between epithelial cells that bacteria can pass through, which in turn 
leads to further immunological responses all leading to inflammation of the intestine.   
Both genetic and environmental factors can lead to an increased risk for 
developing IBD.  Epidemiological studies suggest that having a first-degree relative with 
IBD are up to 20 times more likely to have IBD themselves compared to those without 
affected relatives.  While Mendelian genetics have not been identified to cause IBD, 
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studies have found conserved regions on chromosomes 3, 5, 7, 18, 19 and the X 
chromosome that are linked with both Crohn’s disease and ulcerative colitis and 
additional regions on chromosome 16 and 12 that are specific to Crohn’s disease and 
ulcerative colitis respectively [90].  Multiple genes that have been linked with IBD, 
among them are tumor necrosis factor (TNF) and interleukin-10 (IL-10).  Environmental 
factors that have been tied to development of IBD include the diet, the microflora 
composition of the intestines and habitual use of non-steroidal anti-inflammatory drugs 
[91].  Interestingly, smoking has been observed to protect against ulcerative colitis but 
increases the risk for Crohn’s disease [92, 93].  
Crohn’s disease occurs mostly in the colon and the ileum but can occur anywhere 
along the gastrointestinal tract. Symptoms vary depending upon the location of the flare-
up; if in the esophagus patients may present with dysphagia, heartburn or chest pain 
[94]. Alternatively, gastroduodenal Crohn’s disease causes weight loss, upper abdominal 
pain, nausea and vomiting [95].  The disease is characterized by a cobblestone-like 
appearance of the affected areas; distribution is segmented.  Fistulas (abnormal 
connections between body cavities) and fissures (cuts or tears) are fairly common and 
the ulcers are deep, extending into the submucosa.  The inflammation in Crohn’s disease 
is associated with neutrophil infiltration into the epithelial cells and into the lumen of 
colonic crypts. This leads to the formation of crypt abscesses and eventual destruction of 
the crypt structure and atrophy of the intestine [96].   
Conversely, in ulcerative colitis, the distribution of affected tissue is continuous 
and contained exclusively in the colon and rectum.  Ulcers are superficial and fistulas 
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and fissures are absent.  The inflammation in ulcerative colitis is confined to the 
submucosa and mucosa in contrast to Crohn’s disease where the inflammation affects 
the entire wall of the intestine.  As with Crohn’s disease, neutrophils infiltrate into crypts 
creating abscesses in the affected tissue. There is reduced production of mucins from 
goblet cells and an aberrant Paneth cell distribution associated with the disease [96].    
The colon may be shortened in patients with ulcerative colitis and have thicker intestinal 
walls.  Crypt structure is also altered in ulcerative colitis: crypts are shallower and do not 
extend to the muscle membrane layer [97].    
Currently, there is no cure for IBD and treatment can only alleviate the 
symptoms to allow the person a more normal life.  The main prescribed treatment 
options are the administration of anti-inflammatory drugs and immune-suppressants such 
as corticosteroids and anti-TNFα reagents. Other viable treatments include probiotics 
and prebiotics with the aim to modulate the intestinal microflora to prevent flare-ups of 
the disease [98-100] .   
 
Inflammation-associated Colon Cancer 
 Having IBD increases a person’s risk for developing colon cancer.  Ulcerative 
colitis has the larger effect, increasing cancer risk by as much as 20% while Crohn’s 
disease increases the risk for developing colon tumors by up to 8% [101, 102].   The 
tumors that result from inflammation-associated colon cancer are distinct from those that 
develop in sporadic colon cancer.  These tumors often occur in multiples and are more 
 18 
 
flat and infiltrating.   In addition, inflammation-associated colon tumors are more likely 
to be of a higher grade and mucinous. 
 There are several methods by which the inflammation associated with IBD is 
proposed to promote the development of colon cancer.  In sporadic colon cancer, 
aberrant activation of the Wnt/β‐catenin signaling pathway is an early occurrence in over 
90% of cases.  This activation causes proliferation of cells and prevents older cells from 
apoptosing and sloughing off into the lumen [103, 104].  In the presence of 
inflammation, it has been suggested that β‐catenin activity is upregulated even in the 
absence of genetic mutations to regulatory genes [105]. β‐catenin nuclear accumulation 
can be caused by several inflammatory pathways, including  NF-κB, PI-3K, and Akt 
[104].  The upregulation of β‐catenin via these inflammatory pathways could be a way in 
which inflammation-associated colon cancer can bypass the need for an initiating genetic 
mutation.   Regardless of the lack of initial mutation, the upregulated proliferation 
caused by the inflammation itself increases the risk for developing future mutations. 
 Inflammation can also affect cancer progression and metastasis.  Inflammation 
facilitates epithelial-mesenchymal transition (EMT), which is required for metastasis, 
through the production of cytokines.  TNFα, IL-1 and IL-6 have been observed in vitro 
to induce metastatic behavior in malignantly transformed colon cell lines [106-108].   
 Another important player in the development of inflammation-associated colon 
cancer is the gut microflora.  Colon tumor formation in gnotobiotic mice induced by a 
combination of dextran sulfate sodium (DSS) (an inducer of intestinal colitis) and AOM 
was found to be reduced compared to mice with normal gut microflora [109].  The 
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microbes in the intestines induce the expression of pro-inflammatory cytokines such as 
interferon-γ (IFNγ), IL-10 and IL-17 from immune cells in the gut which in turn can 
promote proliferation of cells [104]. Bacteria may be beneficial for the prevention of 
inflammation-associated colon cancer: treatment with probiotics in rats has been 
demonstrated to inhibit IBD and delay the formation of dysplasia in the colon [110].   
 
Estrogen and Inflammation-associated Colon Cancer and IBD 
 As with sporadic colon cancer, E2 is also associated with a decreased risk for 
developing inflammation-associated colon cancer.  Söderlund et al. observed that men 
with IBD were 60% more likely to develop colon tumors than women with IBD [111].  
In regards to IBD itself, studies observing the occurrence of IBD symptoms in pre-
menopausal women have found that patients with Crohn’s disease, but not ulcerative 
colitis, displayed a worsening of their IBD symptoms during menses [112]. This is the 
point during the menstrual cycle that E2 concentrations are lowest in the body and 
suggests that during the rest of the women’s cycles, the higher E2 concentrations could 
be protecting them from their IBD. 
Animal studies investigating E2’s effect on inflammation and inflammation-
associated colon tumor development have returned conflicting results, however.  Saleiro 
et al. induced inflammation-associated colon cancer in WT and ERβKO female mice 
using DSS and AOM. In these mice, loss of ERβ was associated with an increased 
number and size of polyps as well as a higher grade of dysplasia and inflammatory score 
[113]. Although E2 concentrations were the same in both genotypes in this particular 
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study, it is important to bear in mind that ERβ is the primary ER in the colon and loss of 
the ER would negate most effects of E2 in the affected tissue.   The fact that in this case 
the WT mice were protected demonstrates the efficacy of E2 for preventing 
inflammation-associated colon cancer.  In this same study, WT mice had reduced 
expression of β-catenin, NF-κB, inducible nitric oxide synthase (iNOS), and several pro-
inflammatory cytokines including TNFα, IL-6, IL-17, and IFNγ further demonstrating 
the protective effect of E2 through activating ERβ [113].  
A separate study also using the DSS/AOM model showed that E2 actually 
promoted inflammation-associated colon tumor formation.  That study used intact, 
ovariectomized (OVX), and OVX mice receiving E2 and/or progesterone.  E2 treated 
mice in this case had more polyps, larger polyps, and increased colonocyte proliferation 
compared to control.  Additionally, when they conducted the same study design in 
ERαKO and ERβKO mice they found that loss of either ER was protective against the 
disease, suggesting that both ERs play a role in inflammation-associated colon 
tumorgenesis [114]. Similar to Saleiro et al., the authors conducted an experiment using 
intact female mice. In contrast to the observations of Saleiro et al, Heijmans et al. found 
that intact WT mice had an increase in the formation of polyps. The disparity in the 
outcomes observed between these two studies is likely due to differences in the 
AOM/DSS models used; while both groups injected the mice once with 10mg/kg AOM, 
Saleiro et al. administered a single 2.5% round of DSS whereas Heijmans et al. used 
three rounds of 1.5% DSS [113, 114]. 
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Other animal studies have looked at the effect of E2 and other estrogenic 
compounds on colonic inflammation alone without associated tumor formation.  In DSS 
induced colitis, E2 treatment is correlated with a worsening of inflammation. Heijmans et 
al. observed that E2 in OVX mice increased the disease activity index, IL-6 secretion, 
and proliferation of colon cells [114].  Similarly, Verdú et al found that compared to 
control, E2 treated mice had vastly higher disease severity and histological scores [115].     
Interestingly, however, other models of inducing inflammation have seen a 
protective effect of E2.  A reduction of inflammatory score was observed with E2 in 
dinitrobenzene sulfonic acid (DNB) colitis accompanied by reduced myeloperoxidase 
(MPO) activity suggesting diminished infiltration of polymorphonuclear leukocytes 
(PMN) [115].  2,4,6-Trinitrobenzenesulfonic acid (TNBS) induced colitis has also been 
suppressed by forms of E2: estradiol benzoate reduced expression of macrophage 
migration inhibitory factor and IL-1β, both of which are upregulated during 
inflammation, compared to control [116].  Phytoestrogens, which are plant derived 
compounds that have estrogenic action and are known to bind ERs, have also been 
shown to modulate TNBS induced colitis:  dietary genistein in rats reduced the 
expression of Cox-2 and MPO [117].      
The differential responses to E2 in the different models of inflammation are 
probably due to the mechanisms by which each chemical induces the inflammation in 
the animals.  
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Methods of Inducing Inflammation 
There are several ways to induce experimental colitis.  Primary among them are 
the chemicals DSS and TNBS.  Each causes inflammation using distinct mechanisms 
resulting in colitis that mimics Crohn’s disease (TNBS) and ulcerative colitis (DSS). 
TNBS is administered intrarectally dissolved in ethanol.  The ethanol is proposed 
to increase the permeability of the intestinal lining allowing the TNBS to infiltrate into 
the sub-epithelial spaces of the tissue. Once inside the tissue, the TNBS haptenates 
endogenous colon proteins as well as microbial proteins.  These haptenated molecules 
then elicit an allergic response from the host’s immune system. T helper (TH) 1 and 
TH17 cells express the pro-inflammatory cytokines IL-2, IL-12, IL-18, IFN-γ and TNF-
α and are responsible for the subsequent inflammation [118, 119].  Individual protocols 
for inducing TNBS colitis vary widely depending on the genetic background of the 
animal being used and by the experimental outcomes being measured.  Dosages of 
TNBS range from 0.5 mg to 6 mg per mouse, the ethanol it is dissolved in from 35% to 
50% and the number of administrations range between one and three.  For acute colitis 
studies, only one dose of TNBS is used and the mice are usually sacrificed between 3 
and 5 days afterwards.  Chronic colitis is induced using 2 to 3 rounds of TNBS with 
sacrifice occurring between days and several weeks following the last treatment [119-
121].    
DSS is administered to the animals via the drinking water. Here, the mechanism 
is believed to be a direct cytotoxic effect on intestinal epithelial cells of crypts causing a 
loss of integrity in the mucosal barrier. Bacteria are then able to penetrate into the sub-
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epithelial space where they stimulate immune cells to mount a response [121]. Due to 
the fact that T and B cell deficient mice still developed colitis in response to DSS, it is 
believed that the innate immune system and not the adaptive immune system plays the 
larger role in DSS colitis [122].  Animals often present with weight loss, bloody 
diarrhea, ulcerations, and infiltration of granulocytes [121].  As with TNBS, there are 
models for both acute and chronic colitis using DSS.  Again, acute colitis involves a 
single round of treatment with sacrifice within days and chronic colitis is generally 
induced using three rounds of DSS separated by 14 days on regular water [120]. 
There are other models of experimental colitis; however, they are not widely 
used. Among them are mutant strains of mice, C3H/HeBir and SAMP1/Yit, genetic KO 
and transgenic mice, and administering CD4+ T cells in immunodeficient mice [123-
127].   These models, however, are not as widely used as DSS and TNBS and are not as 
well characterized.  
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CHAPTER II 
DIETARY FISH OIL REDUCES DNA ADDUCT FORMATION WHILE 
ESTRADIOL UPREGULATES APOPTOSIS IN RESPONSE TO DNA DAMAGE 
IN THE RAT COLON* 
       
Introduction 
Colon cancer is the third leading cause of cancer related deaths in both men and 
women. Overall, the disease is the second highest cause of cancer related deaths [1].    
Epidemiological as well as experimental data demonstrates that colon cancer can be 
affected by many lifestyle choices including the diet [128-131].  Fish oil (FO), which 
contains high levels of n-3 polyunsaturated fatty acids (PUFA) has been shown to reduce 
the incidence of colon cancer [32, 132, 133].   One way in which n-3 PUFA can be 
protective against colonic malignancy is by up-regulating apoptosis in colonocytes [43, 
134, 135].  Pathways involved with apoptosis are often dysregulated in cancer 
development resulting in reduced apoptosis of cells which have sustained DNA damage. 
In turn, this results in an increased risk for tumor formation [136, 137].  In-vitro studies 
have shown that treatment of colon cancer cells with docosahexaenoic acid, a n-3 PUFA 
in FO, induced apoptosis compared to n-6 PUFA [138].  In-vivo, n-3 PUFA have been 
shown  to   increase   apoptosis   in   the  colon  of   rats injected with  the  colon  specific  
_____________ 
*Portions of this chapter were reprinted with permission from “Dietary fish oil reduces DNA adduct 
formation while estradiol upregulates apoptosis in response to DNA damage in the rat colon.” By 
Armstrong CM, Allred KF, Allred CD. Dig Dis Sci. 2011 Sep;56(9):2585-94. Copyright 2011 by Springer 
Science + Business Media, LLC. 
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carcinogen azoxymethane (AOM) compared to rats fed n-6 PUFA [48, 49, 139].  In 
addition, n-3 PUFA are associated with reduced DNA damage in the colon.  FO diets 
have been shown suppress formation of AOM induced DNA adducts in the DNA 
damaged colonocytes [48, 49]. Thus far, experiments investigating the protective effects 
of FO and n-3 PUFA on DNA damage in the colon have been conducted in male animals 
and the role of gender has not been fully explored.  
A concern that may be raised with male-only models is that there is the potential 
for sex-specific changes in apoptosis or DNA adduct levels in response to dietary n-3 
PUFAs. It is possible that estrogen could augment the protective effects of n-3 PUFAs.  
Like n-3 PUFAs, estrogen has also been associated with a reduction in colon cancer 
incidence. Based on data provided by the Women’s Health Initiative and other studies, 
post-menopausal women receiving hormone replacement therapy (HRT) have a 
decreased likelihood of developing colon cancer as compared to those receiving a 
placebo [59, 60, 140, 141].  Likewise, estrogen replacement therapy (ERT) has been 
shown to be effective at reducing colon cancer incidence [142].  Animal studies support 
these data.  Rats treated with estradiol (E2) had reduced dimethylhydrazine-induced 
tumor multiplicity [65].  Also, incidence of AOM induced tumors was suppressed in 
both wild type and estrogen receptor α knockout mice when the animals were fed 
estrone, a precursor to E2 [64].  The time during colon cancer development at which 
estrogenic compounds exert their protective effects, however, is unknown. Previous 
studies indicate that malignantly transformed colon cancer cell lines are not responsive 
to treatment with E2 [63, 66, 68].  This has led to the idea that E2 is protective during the 
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initiation and promotion phases of cancer formation.  A study fromthis laboratory has 
shown that in mice treated with AOM, E2 is protective against the development of high 
multiplicity aberrant crypt foci (ACF), which are pre-malignant lesions associated with 
the development of colon tumors. E2 treatment was also associated with an increase in 
apoptosis in colonic crypts in the same mice [63].   These data indicate that E2 is 
protective during the early stages of colon cancer development and could possibly be 
effective as early as the point of DNA damage.  
While both FO and E2 are known to be beneficial for preventing colon cancer, 
the effects of the two together have not been examined.  Previously conducted 
experiments on FO diets have been done in male animals without regard to sex-specific 
effects that might occur in females.  As it stands, it is unknown whether or not FO diets 
have the same protective capabilities in men and women.  It is possible that in the 
presence of E2, FO could prove to be more or less beneficial in women than it is in men.  
In this study, I sought to determine the efficacy of a FO diet in the presence of E2 by 
evaluating DNA adduct formation and induction of apoptosis in colonocytes 
immediately following exposure to carcinogen.  Presented data provide a novel 
understanding of how FO and E2 protect against colon cancer development which in turn 
can lead to improved preventative strategies for men and women to reduce the risk of 
this disease. 
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Materials and Methods 
Animals: Female Sprague-Dawely rats were purchased from Charles River 
Laboratories at 5-6 wk of age.  Rats were singly housed at the Laboratory Animal 
Resources and Research facility at Texas A&M University.  Access to food and water 
was ad libitum.  All procedures were performed under a protocol approved by the 
Institutional Animal Care and Use Committee at Texas A&M University.  
Estradiol, diet, and carcinogen treatments: Seven to 10 week old female rats 
were ovariectomized (OVX) and subcutaneously implanted with either a 2 mg E2 or 
cholesterol (vehicle) implant. At the time of OVX, rats were transferred to a 
phytoestrogen free diet without corn oil (CO) or fish oil (FO).  One week following 
OVX, animals were moved to experimental diets containing either 15% corn oil or 3.5% 
CO and 11.6% FO with half of each of the E2 and vehicle groups receiving either diet. 
Experimental diets were also phytoestrogen free (Pectin Basal Mix, Harlan; 
Indianapolis, IN).  Fresh powdered diet was supplied to the animals each day.  Basal 
diets were identical in vitamin content and each contained 10 g/kg Vitamin E. The FO 
diet contained an additional 58 ppm Vitamin E.  The tissue lipid profiles in the colonic 
tissue resulting from these diets in rats have been previously characterized by Lee et al. 
[143]. Three wk following OVX, the animals were sacrificed at four different time 
points:  0 (no carcinogen), 6, 9, and 12 hr after injection with 15 mg/kg azoxymethane 
(AOM), a colon specific carcinogen. Each group had an n=5 rats per time point except 
for 0 hr CO in which n=4.  Colons were removed and two 1 cm sections were taken from 
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the distal end.  One section of each was fixed in 4% paraformaldehyde (PFA) for 4 hr, 
the other in 70% ethanol overnight prior to embedding in paraffin. 
Plasma E2 measurement:  Blood was collected via cardiac puncture when the 
animals were terminated.  Plasma was extracted by centrifuging the blood samples at 
4°C for 15 min at 2500 RPM. E2 concentrations were determined in a subset of vehicle 
and E2 animals, n=14 from each treatment group, using an Estradiol EIA kit (Cayman; 
Ann Arbor, MI) according to the manufacturer’s instructions.  In brief, the samples were 
diluted 1:10 in enzyme immunoassay buffer and aliquoted into wells.  The samples were 
incubated on the plates with an E2 linked acetylcholinesterase tracer which serves as a 
competitor against E2 present in the plasma sample for binding in the EIA format. The 
amount of tracer bound is inversely proportional to the E2 in the sample. The wells were 
developed with Ellman’s reagent for 75 min and absorbance was read on a plate reader 
at 415 nm.  E2 concentrations were determined by comparison to standards using the 
formula supplied in the kit.  
Immunohistochemistry for O6-methyldeoxyguanosine adducts: Four 
micrometer sections were taken from the 70% EtOH fixed tissues.  Sections were 
deparrafinized and rehydrated.  Endogenous peroxidase was quenched using 3% H2O2 in 
methanol for 40 min.   Antigen retrieval was achieved by microwaving in 10 mM citrate 
buffer for 10 min.  Following washing, slides were incubated with the primary anti-O6-
methyldeoxyguanosine antibody (Squarix Biotechnologies, Germany) at a 1:500 dilution 
at 4°C overnight.  The primary antibody was detected using the labeled streptavidin–
biotin method (LSAB2; Dako, Denmark) as per the manufacturer’s directions; tissues 
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were incubated in a humidified chamber for 10 min each of a biotinylated secondary 
antibody and streptavidin conjugated to horseradish peroxidase separated by rinses in 
PBS.  Subsequently, the slides were incubated in 1% diaminobenzidine (DAB) (Sigma-
Aldrich; St. Louis, MO) in PBS for 6 min followed by dehydration and coversliping.  
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
assay: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) assays were performed using the ApopTag Peroxidase in situ Apoptosis 
Detection Kit (Millipore; Billerica, MA) following the manufacturer’s instructions with 
slight modifications.  Briefly, PFA fixed tissues were rehydrated then treated with 10 
μg/mL Proteinase K for 3 min at 37°C.  Endogenous peroxidase was blocked using 0.3% 
H2O2 in methanol for 30 min.  Tissues were incubated at room temperature (RT) for 20 
sec in equilibration buffer followed by 1 hr at 37°C in reaction buffer plus TDT enzyme.  
Omission of the TDT enzyme was used as a stain control.  Next, slides were placed in 
stopwash solution for 10 min followed by incubation for 30 min at RT in anti-
digoxigenin in a humidified chamber. Point five percent DAB for 20 sec was used as the 
chromagen and nuclei were counter stained in 0.5% methyl green for 5 sec.  Lastly, 
slides were dehydrated and coversliped. 
Tissue analysis: Twenty intact crypts were evaluated per animal for each 
immunohistochemistry stain.  Crypts were symmetrically bisected and the right halves of 
the crypts were further divided into equal thirds along their height to evaluate differences 
based on crypt cell position.  For the O6-methyldeoxyguanosine (O6-MedG) DNA 
adduct analysis, staining intensity of individual nuclei were analyzed using ImageJ, a 
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program which returned values based on the color intensity of the selected image, and 
each value was exported into Microsoft Excel.  A background value taken from an 
uninvolved region of the tissue was subtracted from each image to account for non-
specific staining within that tissue.   The mean staining intensity of the entire crypt for 
each rat as well as the mean staining intensity for individual tertiles of the crypts was 
determined and compared across time points. 
For apoptosis, the number of positive cells per crypt column was divided by the 
total number of cells for that column to obtain the proportion of apoptotic cells.  The 
same procedure was used to analyze each tertile. The percentages of apoptotic cells were 
compared across regions of the crypt and time points after AOM injection. 
Statistical analysis: A Student’s t test was performed for analysis of plasma E2 
data.  One-way ANOVA was used for all other outcomes.   ANOVA data was run in 
Minitab 15 and t tests were performed in Microsoft Excel.  All values are listed as group 
means with error bars presented as standard error of the mean. 
 
Results 
Plasma E2 concentrations: Plasma E2 levels were measured in both vehicle 
control and E2 treated rats.  While some studies have indicated that foods high in 
Vitamin E, such as FO, may increase E2 production within an animal, I do not believe 
this to be the case in this study as diet was seen to have no significant effect on 
circulating blood E2 levels.  CO fed vehicle treated rats had a mean plasma E2 
concentration of 0.22 nmol/L while FO fed E2 treated animals had a concentration of 
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0.21 nmol/L.  Rats receiving E2 had plasma E2 concentrations of 2.42 nmol/L and 2.47 
nmol/L on the CO and FO diets respectively. This level falls within the physiological 
range for premenopausal women. 
Fish oil reduces formation of O6-methyldeoxyguanosine adducts: 
Immunohistochemistry was used to evaluate the formation of O6-MedG adducts in the 
colon of rats at 0, 6, 9, and 12 hr following injection with AOM (Figure 2.1 A-D).  When 
evaluating the full height of the crypt, FO-fed animals had significantly reduced amounts 
of DNA adducts compared to CO-fed rats at 9 hr and 12 hr post treatment with AOM 
(Figure 2.1 E and F).  A similar magnitude in the decrease in DNA adducts was 
observed between diet groups regardless of the presence or absence of E2.  The largest 
reductions in adduct staining intensity in response to diet were detected at 12 hr for both 
E2 and vehicle treated animals.   Different populations of cells reside in different 
locations of the crypt; actively proliferating cells and stem cells are generally located in 
the bottom third while the top, lumenal, third contains older cells which are about to be 
sloughed off [144]. To see if there were differences in O6-MedG staining intensity with 
regards to cell location in the crypt, each crypt was divided into equal thirds 
latitudinally.  All crypt positions and times after AOM were evaluated; only the 
statistically significant regions and times are presented.  As seen in Table 2.1, significant 
differences between the two dietary groups were seen in all three thirds of the crypt: 
bottom, middle, and top, at both 9 hr and 12 hr.  In addition, E2 treated FO-fed rats also 
had significantly fewer DNA adducts than the E2 treated CO-fed rats at 6 h post AOM in 
the bottom third of the crypt.  No significant differences were seen between groups 
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receiving the same diet in response to E2 treatment in any location of the crypt for any 
time point (Figure 2.1 G and H). 
 
Figure 2.1. Effect of diet and E2 on staining intensity of O6-MedG DNA adducts. 
Representative photographs of O6-MedG adduct stained crypts in corn oil (A), corn oil + 
E2 (B), fish oil (C), and fish oil + E2 (D) treated rats 9 h post AOM. (E) Adducts in the 
colon of corn oil verses fish oil fed rats. (F) Adducts in the colon of corn oil + E2 verses 
fish oil + E2 rats. (G) Adducts in the colon of corn oil verses corn oil + E2 rats. (H) 
Adducts in the colon of fish oil verses fish oil + E2 rats. Data depicted as means ± 
standard error. * P<0.05; ** P<0.01 between groups for that time point. 
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Table 2.1. Significant diet effects on DNA adduct staining intensity by time and location. 
 
 
 
Dietary effects on apoptosis: In an effort to determine whether dietary FO in the 
presence or absence of E2, could enhance induction of apoptosis in colonocytes, the 
percentage of apoptotic cells was evaluated using a TUNEL assay in the colon of rats at 
0, 6, 9, and 12 hr following injection with AOM (Figure 2.2).  For all treatment groups, 
apoptosis occurred predominately in the bottom third of the crypt with decreasing levels 
in the middle to the top (Figure 2.3A).  A significant overall diet effect was observed at 
12 hr post AOM between the vehicle treated groups; FO fed rats had decreased apoptosis 
as compared to CO fed rats (Figure 2.3B).   No differences in apoptosis were observed in 
response to diet in the E2 treated rats (Figure 2.3C).    
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2.3A).  When divided out into individual time points, significant E2 effects were 
observed in the CO fed rats in the top third of the crypt 12 hr post AOM; E2 treatment 
resulted in increased apoptosis over the vehicle animals.  The FO fed groups had 
significant E2 effects in the bottom and top thirds of the crypt 12 hr post AOM with the 
E2 treated groups having increased apoptosis.  (Table 2.3).   
 
Table 2.2. Significant effects of diet on apoptosis by cell location and time 
 
 
Table 2.3. E2 effects on apoptosis by cell location and time 
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Figure 2.3. Effect of diet and E2 on apoptosis. (A) Location of apoptosis. Bars without a 
common letter differ, P<0.01. (B) Apoptosis in the colon of corn oil verses fish oil fed 
rats. (C) Apoptosis in the colon of corn oil + E2 verses fish oil + E2 rats. (D) Apoptosis 
in the colon of corn oil verses corn oil + E2 rats. (E) Apoptosis in the colon of fish oil 
verses fish oil + E2 rats. Apoptosis in the colon of rats sacrificed at 0, 6, 9, and 12 hr 
after injection with AOM was analyzed using a TUNEL assay. Data depicted as means ± 
standard error. * P<0.05; ** P<0.01 between groups for that time point. 
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Discussion  
 Evidence exists that both E2 and FO are protective against the formation of colon 
cancer [32, 60, 132, 133, 142].  For FO, decreased levels of DNA adducts and an 
induction of apoptosis have been shown to be mechanisms of action [43, 49, 135, 139].  
E2 treatment is linked to increased apoptosis [145] and reduced numbers of aberrant 
crypt foci [63].  Thus far, experiments investigating FO diets at the point of DNA 
damage have been conducted in male animals and the effects of FO and E2 within the 
same animal have not been thoroughly examined.   Understanding the potential 
interactions between FO and E2 could lead to clinically relevant discoveries for dietary 
recommendations and hormone treatments to better help reduce the risk of colon cancer 
in the future. 
The first part of this study examined the effects of a FO or CO diet in female rats, 
in the presence or absence of physiological concentrations of E2, on O6-MedG DNA 
adduct formation.  O6-MedG DNA adducts were decreased 9 and 12 hr after AOM 
injection in rats fed the FO diet compared to the CO diet, both in the vehicle and E2 
treated groups.  This observation is in accord with previous studies which have been 
conducted in male animals [49, 139].  I detected significant reductions in DNA adduct 
formation with dietary FO 9 and 12 hr following AOM injection with the largest 
reduction occurring at the 9 hr time point.  In regards to adduct staining intensity 
localization, these data demonstrated that FO fed rats had reduced staining intensity 
throughout the three tertiles (top, middle and bottom) of the crypt compared to CO fed 
rats.  Collectively, these data suggest that FO is equally protective against O6-MedG 
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adduct formation regardless of the presence or absence of E2. The fact that E2 does not 
alter the ability of a diet high in FO to suppress adduct formation is important because it 
identifies this as a primary mechanism of reducing colon tumor formation in both males 
and females. 
 Next I investigated the effects of E2 on DNA adduct formation independent of 
diet group to determine if E2 is protective against DNA damage in the colon.  An earlier 
study in this laboratory demonstrated that while E2 induces physiological changes in 
non-malignant colonocytes, these effects are lost following malignant transformation of 
the same cells [63]. This implicates a role for E2 in the chemoprevention of colon cancer 
at the early stages of tumor development.  DNA adducts are indicative of DNA damage 
within a cell which occurs prior to malignant transformation.  Phytoestrogens, plant 
derived compounds known to have estrogenic properties, can affect DNA adduct 
formation in the colon.  One study detected an increase in 2-amino-1-methyl-6-phenyl-
imidazo[4,5-b]pyridine (PhIP)  induced DNA adducts in the colon of rats fed genistein, a 
soy derived phytoestrogen, [146] whereas Giri et al. 1995 observed a reduction in 
DMBA-induced DNA adducts in genistein fed mice [147].  Other studies have examined 
the role of gender on DNA adduct formation in the colon and have found no change in 
PhIP induced adducts between male and female rats [148].  It is likely that the differing 
effects of estrogenic compounds on adduct formation in the colon are dependent on the 
type of adduct being analyzed.  When I examined O6-MedG adduct staining intensity in 
the colon following AOM exposure with respect to E2 treatment, no significant 
differences were seen.   This implies that while E2 is protective against AOM induced 
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colon carcinogenesis, it is not due to a protection against O6-MedG DNA adduct 
formation though these results may be specific to the type of adduct evaluated. 
In normal colonic tissue, stem cells at the base of the crypt give rise to epithelial 
cells [144].  In healthy colon tissue, apoptosis is generally localized to the lumenal 
region of the crypt and occurs in fully differentiated cells [149].  In response to DNA 
damage resulting from carcinogen treatment, apoptosis in colonocytes occurs mostly at 
the base of the crypt near the actively proliferating cells [51].  On average, the largest 
percentage of apoptotic cells was observed 9 hr post AOM injection in this study.  These 
data coincide with the time point with the highest average staining intensity for O6-
MedG DNA adducts and indicates that the level of apoptosis within the colonic crypts 
may be directly related to formation of DNA adducts.  Prior studies by other groups have 
seen an overall lack of effect of a FO diet on apoptosis except in the lumenal third of the 
crypt where the FO diet had significantly increased apoptosis compared to CO fed 
animals [49].  In contrast to data previously published in male animals, an increase in 
apoptosis was observed in rats on the CO diet not receiving E2 12hrs post AOM 
compared to FO fed rats.  This was attributable to increased apoptosis in the bottom third 
of the colon crypts and was not observed in CO fed animals in the presence of E2 
treatment.  The reasons for the contrast between this data and that seen in male animals 
are not clear and will require further investigation, but it highlights the possibility that n-
6 PUFAs may have unique physiological effects in postmenopausal women compared to 
pre-menopausal women with higher circulating levels of E2.  There were no differences 
seen between diet groups in the lumenal third of the crypts in relation to apoptosis. 
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Similarly, human trials conducted in both men and women have shown that increased 
consumption of fatty fish does not induce apoptosis in the colonic crypts [150].  
Although apoptosis was not increased in the female animals in this study in response to a 
FO diet, evidence remains that n-3 PUFAs are protective against colon cancer.  In 
women, however, induction of apoptosis by dietary n-3 PUFAs may not be a primary 
method of protection. 
 When the effects of E2 on apoptosis were analyzed within the same diet groups, it 
was seen that E2 treatment resulted in a significant increase in apoptosis independent of 
diet at the 12 hr time point following induction of apoptosis with AOM.  Another study 
in this laboratory has demonstrated that apoptosis is upregulated in the colon of mice by 
E2 8 wk after AOM exposure at the ACF stage of colon cancer development [63].  This 
fact, combined with the increase in apoptosis observed in this study, implies a potential 
up-regulation of apoptosis at the point of DNA damage that persists through later stages 
of tumor formation.  E2 treatment resulted in significant increases in apoptosis in the 
lumenal third for both diet groups and the bottom third of the crypts in FO fed animals.  
The largest increase in apoptosis in response to E2 occurred in the lumenal third of the 
crypts. In this region, the levels of apoptosis were still increasing at the 12 hr time point 
in E2 treated animals compared to control.  This suggests that E2 can upregulate apoptosis 
in the lumenal third of crypts in response to DNA damage which is important because 
these colonocytes are older and as such may be more prone to DNA damage compared 
to those in the lower regions of crypt.   Additionally, E2 upregulated apoptosis in the 
bottom third of the crypts in the FO animals; this region is associated with active 
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proliferation.  By inducing apoptosis in this area of the crypt, DNA damaged cells have a 
reduced chance of proliferating and propagating any DNA damage into new cells.  
Further study is required to determine whether the levels of apoptosis continue to 
increase after 12 hr and for how long the levels of apoptosis remain elevated.  The 
observed induction of apoptosis in response to E2 treatment demonstrates for the first 
time that E2 is protective against colon cancer development as early as the point of DNA 
damage. 
In conclusion, these studies indicate that regardless of the estrogen status, a FO 
diet is effective at reducing O6-MedG DNA adducts in rats injected with AOM.  These 
data are important because they show that FO diets are likely to be equally protective in 
men and women against O6-MedG DNA adduct formation in the colon.  In regards to 
apoptosis, this study is the first to observe that E2 is capable of upregulating apoptosis in 
colonic crypts within hours of DNA damage.  In conjunction with previous data from 
this laboratory [63], these data support the idea that E2 is protective prior to malignant 
transformation.  Specifically, my data demonstrate that E2 induces apoptosis in 
colonocytes at the point of DNA damage.  Collectively, these data are a critical step in 
understanding the protective role that n-3 PUFAs and E2 play in lowering colon cancer 
incidence and will be important in developing chemopreventative strategies for reducing 
the occurrence of this disease. 
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CHAPTER III 
A NOVEL SHIFT IN ESTROGEN RECEPTOR EXPRESSION OCCURS AS 
ESTRADIOL SUPPRESSES INFLAMMATION-ASSOCIATED                         
COLON TUMOR FORMATION* 
 
Introduction 
 Women have a reduced risk for developing colon cancer as compared to men.  
This protection is lost, however, once a woman reaches menopause,  suggesting estrogen 
as a protective agent against colon tumor development.  Data from the Women’s Health 
Initiative (WHI) study as well as other clinical trials have confirmed this idea as it has 
been documented that post-menopausal women on either hormone replacement therapy 
(HRT) or estrogen replacement therapy (ERT) have a reduced incidence of developing 
colon cancer [58-62].   
Animal studies have also investigated the role for estrogens in abating colon 
cancer occurrence: dimethylhydrazine-induced colon tumor number was reduced in rats 
receiving estradiol (E2) [65].  Additionally, the multiplicity of tumors induced by 
azoxymethane (AOM) was suppressed by orally administered estrone, a precursor to E2, 
in both estrogen receptor (ER) α knockout (ERαKO) and wild type (WT) mice [151].   
  
_____________ 
*Portions of this chapter were reprinted with permission from “A novel shift in estrogen receptor 
expression occurs as estradiol suppresses inflammation-associated colon tumor formation” by Armstrong 
CM, Billimek AR, Allred KF, Sturino JM, Weeks BR, Allred CD. Endocr Relat Cancer. 2013 Jun 
27;20(4):515-25. Copyright 2013 by Society for Endocrinology. 
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Not only has estrogen been linked to reduced incidence of sporadic colon cancer, 
but data also show that the risk for inflammation-associated colon cancer may be 
influenced by E2.  Epidemiological studies have demonstrated that women have a lower 
risk for developing this disease as compared to men which may be due to the presence of 
estrogens [111].  The mechanism mediating this protection, however, is poorly 
understood.  It is important to investigate this subtype of colon cancer and to develop 
strategies against the disease because the risk for being diagnosed with colon cancer is 
increased in persons suffering from inflammatory bowel disease (IBD).  Both ulcerative 
colitis and Crohn’s disease are associated with an increased cancer risk [101, 152, 153].  
In fact, patients with inflammation-associated colon cancer have a worse prognosis and 
survival rate compared to those with sporadic colon cancer [154].  The tumors that 
develop have distinct characteristics compared to those from sporadic colon cancer; they 
are commonly flat and infiltrating and often occur in multiples. Additionally, there is a 
higher incidence of high-grade, mucinous carcinomas in inflammation-associated colon 
cancer.  The mechanism linking IBD and colon tumor formation is not yet fully 
understood but is likely associated with enhanced occurrence of DNA mutations in 
colonic epithelia due to chronic inflammation.  
 The focus of the present study was to investigate the timing of when E2 may be 
administered and be protective against inflammation-associated colon tumor formation.  
While the WHI study did find that HRT prevented osteoporosis, reduced fractures, and 
lowered the incidence of colorectal cancer, the study was ended prematurely due to an 
observed increase in risk for invasive breast cancer and heart disease.  In a follow-up to 
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the WHI study, it was observed that the protective effect of HRT in protecting against 
colon cancer was completely lost in as few as 3 years after discontinuing HRT [155].  
This indicated that the timing of exposure to E2 is an important factor when considering 
E2 as a chemoprotective agent.  By using an experimental protocol in which I delayed E2 
treatment in ovariectomized mice until after colon cancer had been initiated I sought to 
determine whether E2 could protect against colon carcinogenesis even after DNA 
damage had occurred and tumors had been initiated. To do so, I used AOM and dextran 
sulfate sodium (DSS), an inflammatory reagent which mimics ulcerative colitis in 
humans.  The presented data provide novel insight into the timing of when E2 exposure 
is beneficial for colon cancer prevention and implicate a role for E2 in inflammation-
associated colon cancer.   
 
Materials and Methods  
Animals: C57Bl6/J mice heterozygous for ERβKO (+/-) were originally 
obtained from The Jackson Laboratory.  The mice were housed at the Laboratory 
Animal Resources and Research facility at Texas A&M University.  Mice were bred to 
produce WT and ERβKO offspring and genotype was confirmed using genomic tail 
DNA.  All procedures were performed under a protocol approved by the Institutional 
Animal Care and Use Committee at Texas A&M University.  
Generation and identification of colon tumors:  Female WT and ERβKO mice 
were ovariectomized and implanted with a 20 mg cholesterol (Sigma-Aldrich; St. Louis, 
MO) containing pellet subcutaneously on the back of the neck (Figure 3.1A).  At the 
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time of surgery, mice were placed on a semi-purified phytoestrogen-free diet (AIN-76, 
Lab Supply; Highland Village, TX) and allowed ad libitum access to food and water.  
Two wk following surgery, the mice were injected with a single 12.5 mg/kg injection of 
AOM (Sigma-Aldrich; St. Louis, MO).  Inflammation of the colon was induced 1 week 
after AOM injection by way of two 6-day regimens of 2.5% dextran sulfate sodium 
(DSS) solution in the drinking water separated by 2 wk between regimens.  A fresh DSS 
solution was supplied to the mice on days 3 and 5 of each regimen.  One week following 
the final DSS treatment, the cholesterol containing pellets were removed and the mice 
were randomly assigned to either E2 or control groups with half of the mice receiving a 
new 20 mg cholesterol pellet and the other half receiving a pellet composed of 19 mg 
cholesterol + 1 mg E2.  After 8 more wk, the mice were injected with bromo-
deoxyuridine (BrdU) and sacrificed 2 hr later.  Blood was collected via cardiac puncture.  
The colon was resected and individual masses were cassetted and fixed in 4% 
paraformaldehyde (PFA) for 4 hr.  The size of each mass was assessed using calipers.  
Uninvolved tissue from the most distal region of the colon not containing visible masses 
was cassetted and fixed as well.  Tumors were classified by a board certified pathologist 
blinded to treatment groups following H&E staining of the sections. 
 Ovariectomized control mice, both WT and ERβKO, were kept in parallel with 
the AOM/DSS mice.  These mice were handled in the same manner as the tumor bearing 
mice with the exception of not receiving AOM and DSS.  At the time of sacrifice, 1 cm 
sections were cut from the distal colon, cassetted, and fixed in 4% PFA.  Additionally, 
mucosal scrapings were collected and flash frozen in liquid nitrogen for RNA isolation. 
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E2 treatment in non-AOM/DSS mice: A second set of non-AOM/DSS mice 
were used to observe the effects of E2 in healthy tissues. Mice were individually housed, 
randomly assigned to a control or E2 treatment group based on age and weight, and 
given a phytoestrogen free diet. All mice were ovariectomized and control animals were 
given a 20 mg cholesterol pellet while E2 mice were given a 19 mg cholesterol + 1 mg 
E2 pellet implanted subcutaneously on the back of the neck. Sacrifice occurred on day 
72. At time of sacrifice, blood was collected through cardiac puncture. The colon was 
resected and 1cm sections from the distal end were cassetted and fixed in 4% PFA. 
Plasma E2 levels:  Whole blood was collected at the time of sacrifice.  Plasma 
was obtained by centrifuging the samples at 2500 RPM for 15 min at 4°C.  Plasma E2 
was measured using the Estradiol EIA kit (Cayman; Ann Arbor, MI) according to the 
manufacturer’s instructions.  Samples were diluted 1:10 and the reaction was allowed to 
develop for 75 min.   Absorbance was read on a plate reader at 415 nm and final E2 
concentrations were determined by comparison to standards using the formula supplied 
in the kit.  
Immunohistochemistry for ERβ, ERα and BrdU: Four micrometer sections 
were taken from the PFA fixed tissues.  Sections were deparrafinized and rehydrated.  
Endogenous peroxidase was quenched using 3% H2O2 in methanol for 30 min and 
antigen retrieval was achieved by microwaving in 10 mM citrate buffer for 20 min.  
Slides were then incubated in the primary antibody, rabbit-anti-ERβ (Pierce; Rockford, 
IL) diluted 1:50, rabbit-anti-ERα (Santa Cruz Biotechnology; Santa Cruz, CA) diluted 
1:50 or anti-BrdU (Roche; Basel, Switzerland) diluted 1:20 at 4°C overnight in a 
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humidified chamber.  During each stain, the primary antibodies were left off of a single 
slide to serve as a negative control. The following morning, the slides were washed and 
then incubated in the secondary antibodies, goat-anti-rabbit-HRP (Santa Cruz 
Biotechnology; Santa Cruz, CA) diluted 1:50 or goat-anti-mouse-HRP (Abcam; 
Cambridge, MA) diluted 1:250 for the ERβ and BrdU stains respectively.  For ERα, the 
VectaStain ABC Kit (Vector Laboratories; Burlingame, CA) was used for the secondary. 
A 1% diaminobenzidine (DAB) (Sigma-Aldrich; St. Louis, MO) solution in PBS was 
used as the chromagen and Meyer’s haematoxylin was used as the counter stain.  Lastly, 
slides were dehydrated and coverslipped. 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
assay:  The ApopTag Peroxidase in situ Apoptosis Detection Kit (Millipore; Billerica, 
MA) was used for the terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling (TUNEL) assays following the manufacturer’s instructions with slight 
modifications.  PFA fixed tissues were rehydrated and treated with 10 μg/mL proteinase 
K for 3 min at 37°C.  Endogenous peroxidase activity was blocked using 0.3% H2O2 in 
methanol for 30 min.  Tissues were incubated at room temperature (RT) for 20 sec in 
equilibration buffer and then incubated for 1 hr at 37°C in reaction buffer plus TDT 
enzyme.  The TDT enzyme was omitted from an individual section as a negative control 
for the stain.  Subsequently, slides were placed in stopwash solution for 10 min followed 
by 30 min at RT in anti-digoxigenin in a humidified chamber. A 0.5% DAB solution for 
20 sec was used as the chromagen and nuclei were counter stained in 0.5% methyl green 
for 5 sec.  Lastly, slides were dehydrated and coverslipped. 
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Immunohistochemistry analysis:  The proliferation and apoptosis stains were 
analyzed in the same manner.  In the uninvolved tissue (the most distal region of the 
colon not containing a mass), crypts were symmetrically bisected and the right halves of 
20 crypts were analyzed per animal.  The total number of positively stained cells was 
divided by the total number of cells in the crypt column to generate the percentage of 
apoptotic or proliferative cells for each column.  For the tumor sections, 250 cells from 
four distinct regions of each tumor were analyzed.  Analysis of the ERβ and ERα stains 
was conducted using the image analysis software, Cell Profiler, in conjunction with 
HKCellCounter, a pipeline designed to specifically identify nuclei within a designated 
region and return values based on the staining intensity of each identified nuclei.  The 
pipeline identifies nuclei based on parameters, such as size and shape, set by the user 
within a specified area of a photograph.  Twenty intact crypts were analyzed for each 
uninvolved and non-AOM/DSS sample.  Four images of distinct locations from each 
tumor were analyzed to determine expression levels in the adenocarcinomas.  The same 
parameters were used for each photomicrograph to ensure consistency between analyses. 
rtPCR for ERα:  RNA was isolated using trizol from tumors in the tumor 
bearing mice and the mucosal scrapings in the non AOM/DSS treated mice.  cDNA was 
produced from the RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche; 
Basel, Switzerland) as per the manufacturer’s instructions: 1 μL of the diluted sample 
was mixed with a random hexamer primer, an anchored-oligo(dT)18 primer and water.  
Samples were then placed in a thermal cycler for 10 min at 65°C.  Next, reaction buffer, 
RNAse inhibitor, deoxynucleotide mix, and reverse transcriptase were added to the 
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sample and then returned to the thermal cycler for 10 min at 25°C followed by 60 min at 
50°C and 85°C for 5 min.  Samples were then stored at -20°C. 
 The SYBR Green method was used to assess mRNA content of the samples.  
Primers against ERα and 18s sequences were produced by Sigma-Aldrich with the 
following sequences: ERα-Forward; 5’-GACCAGATGGTCAGTGCCTT, ERα-Reverse; 
5’-ACTCGAGAAGGTGGACCTGA, 18s-Forward; 5’-TCAAGAACGAAAGTCGGAGGT, 
18s-Reverse; 5’-GGACATCTAAGGGCATCACAG.  Two microliters of cDNA were 
mixed with 2.5 μL of forward and reverse primer, 9.5 μL SYBR green and 11 μL water.  
Prepared samples were loaded into 96 well reaction plates and run for 45 cycles. 
Samples were run in triplicate. ERβ RNA expression was not analyzed due to the 
previously collected protein data for ERβ. 
Statistical analysis:  The tumor number outcome was analyzed using a bootstrap 
with 1000 replications, a statistical test that compares the medians of groups.  In vivo 
apoptosis data was analyzed using a Poisson regression model allowing for over-
dispersion and statistical inference was carried out by testing model coefficients 
corresponding to group comparisons with control using a Wald test.  One-way ANOVA 
was used for the remaining outcomes.  ANOVA was run using Minitab 15 and the 
bootstrap, Poisson regression and Wald test were performed using the statistical software 
‘R’.   
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Results 
Plasma E2 concentrations: Plasma E2 concentrations were measured in all mice.  
WT and ERβKO mice receiving E2 pellets both averaged 0.8 nmol/L which is 
marginally lower than peak E2 concentrations in a premenopausal non-pregnant woman 
and well below the levels experienced in pregnancy [156, 157].  Non-ovariectomized 
mice reach peak E2 levels during estrus at around 0.24 nmol/L [158].  Animals not 
receiving E2 had mean plasma E2 concentrations of 0.03 nmol/L and 0.04 nmol/L for WT 
and ERβKO mice respectively.  These concentrations are less than half the concentration 
of plasma E2 associated with postmenopausal women [159]. 
Tumor multiplicity and area is reduced with E2 treatment: To determine 
whether administration of E2 following initiation of DNA damage could decrease the 
formation of colon tumors, colon tumor multiplicity and area were measured in both WT 
and ERβKO mice following the study design described (Figure 3.1A). Tumors were 
characterized by a board certified pathologist blinded to treatment groups.  The median 
number of tumors per animal was decreased by nearly 50% in the presence of E2 in the 
WT mice (P = 0.05) (Figure 3.1B).  In comparison, no significant change in median 
tumor number was observed in the ERβKO mice.  In the absence of E2, ERβKO mice 
had significantly reduced tumor number compared to WT controls (P = 0.05).  In regards 
to the mean size of each tumor, E2 treatment resulted in a 30% reduction in tumor area in 
the WT mice (P = 0.031).  Again, the response to E2 was not observed in the ERβKO 
mice. Both control and E2 treated ERβKO mice had a significant reduction in tumor size 
compared to WT control mice (P= 0.001 and P = 0.003) (Figure 3.1C).   
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Figure 3.1.  Effect of E2 on tumor number and area. (A) Study design. (B) Median 
number of tumors per mouse +/- median absolute deviation. (C) Mean area of tumors ± 
SEM., n=6 mice in the WT and ERβKO control groups, n=7 mice in the WT E2 group 
and n=5 mice in the ERβKO E2 group. Bars without a common letter differ, P<0.05. 
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Cellular proliferation increases in WT E2 treated mice at the tumor stage:  
Proliferation of epithelial cells within the tumors and uninvolved colonic crypts was 
analyzed using immunohistochemistry for BrdU in order to investigate potential 
mechanisms for the reduction in tumor multiplicity and size observed in the E2 treated 
WT mice.  Surprisingly, E2 treatment resulted in significantly increased proliferation in 
both the uninvolved tissue and the adenocarcinomas in WT mice compared to non-E2 
treated controls (P = 0.043 and P = 0.017 respectively) (Figure 3.2A-B).  In the 
uninvolved WT tissue, E2 roughly doubled the amount of proliferation compared to non-
E2 treated mice. In the adenocarcinomas there was a 30% increase in proliferation.  
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Figure 3.2.  Colonocyte proliferation was evaluated in the tumors and uninvolved colon 
tissue of WT and ERβKO mice using immunohistochemistry. (A) Proliferation in 
uninvolved colon tissue and (B) proliferation in the tumors.  Values  are  mean percent 
of positively stained cells ± SEM, n=6 animals in the WT and ERβKO uninvolved 
control  groups, n=7  animals  in  the uninvolved  WT E2 group and n=5 in the 
uninvolved ERβKO E2 group.  In B, n=6 mice in the WT control group, n=7  WT E2 
mice, n=6 ERβKO control mice and n=5 ERβKO E2 mice.  Bars without a common letter 
differ, P ≤ 0.05. 
 
Apoptosis is down regulated by E2 at the tumor stage in WT mice:  Having 
observed increases in proliferation in response to E2, levels of apoptosis were also 
evaluated in the adenocarcinomas and uninvolved tissue using a TUNEL assay.  No 
significant differences were observed in the percentage of apoptotic cells in uninvolved 
tissues in response to E2 treatment for either WT or ERβKO mice (Figure 3.3A).  In the 
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adenocarcinomas, E2 treatment resulted in a 25% decrease in apoptosis in WT mice (P = 
0.039) and no significant difference in ERβKO mice (Figure 3.3B).  Contrarily, in the 
non-AOM/DSS treated mice, the presence of E2 was correlated with increased apoptosis 
in the colonic crypts and no changes in proliferation (Figure 3.4A-B). 
 
Figure 3.3.  Effect of E2 on Apoptosis. Cellular apoptosis was evaluated in the tumors 
and uninvolved colon tissue of WT and ERβKO mice using a TUNEL assay. (A) 
apoptosis in uninvolved colon tissue and (B) apoptosis in the tumors.  Values  are  mean 
percent of positively stained cells ± SEM, n=6 animals in the WT and ERβKO 
uninvolved control  groups, n=7  animals  in  the uninvolved  WT E2 group and n=5 in 
the uninvolved ERβKO E2 group.  In B, n=6 mice in the WT control  group, n=7  WT E2 
mice, n=6 ERβKO control mice and n=5 ERβKO E2 mice.  Bars without a common letter 
differ, P ≤ 0.05. 
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Figure 3.4.  Colonocyte proliferation and apoptosis were evaluated in non-diseased WT 
and ERβKO mice. (A) Study design. (B) Percent of proliferative cells in the colonic 
crypts ± SEM. (C) Percent of apoptotic cells in the colonic crypts +/- SEM. n=10 mice 
for each of the WT control and ERβKO E2 groups and n=8 mice for the WT E2 and 
ERβKO control groups.  Bars without a common letter differ, P ≤ 0.05. Data collected 
by Autumn Billimek [73]. 
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ERβ protein expression declines as tumors develop: In order to investigate 
physiological changes associated with the observed reduction in tumor area and number 
in response to E2, ER expression levels were measured. ERβ was evaluated using 
immunohistochemistry to observe the effects of inflammation-associated carcinogenesis 
on protein levels of ERβ in WT mice (Figure 3.5).  Tumor sections were compared to 
uninvolved sections from tumor bearing mice as well as to normal tissue from normal, 
non-AOM/DSS treated mice from the same animal experiment.  Normal colon tissues 
had the highest staining intensity for ERβ.  Uninvolved sections of colon had a 
significant reduction in staining intensity compared to normal tissues (P = 0.0007 and P 
= 0.002 for control and E2 treated respectively).  Analysis of the tumor sections 
demonstrated even further reduction in staining intensity when compared to non-
AOM/DSS tissues and levels were significantly lower in the tumor when compared to 
uninvolved tissue samples from the same animal (P < 0.0001).  The reduction in ERβ 
expression concentrations was not affected by the presence of E2. 
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Figure 3.5.  ERβ expression was evaluated in the tumors, uninvolved, and normal colon 
tissue of WT mice using immunohistochemistry. (A) Quantification of staining intensity.  
Values  are  mean staining intensity of the tissues ± SEM, n=7 mice in the normal, non-
AOM/DSS group, n=6 mice for WT cholesterol groups and n=7 mice in the WT E2 
groups.  Bars without a common letter differ, P ≤ 0.0001. B-G, Representative 
photographs of staining for ERβ in an ERβKO colon (B), normal, non-AOM/DSS 
treated WT (C), uninvolved WT-control (D), WT-control tumor (E), WT-E2 uninvolved 
(F), and WT-E2 tumor tissues (G).  
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ERα mRNA and protein expression increases as tumors develop:  In addition 
to measuring ERβ, ERα was also assessed using rtPCR in the tumor and non-AOM/DSS 
colon tissues.  mRNA collected from mucosal scrapings from non-AOM/DSS treated 
mice in the same animal experiment was compared to mRNA from tumor samples to 
assess if ERα expression was altered as the tissue progressed to a malignant state (Figure 
3.6A).  There was a 300-fold increase in ERα expression in the tumors compared to 
normal mucosa in WT mice not receiving E2 (P = 0.021).  Adenocarcinomas from 
ERβKO mice not receiving E2 had a 200-fold increase in ERα mRNA expression 
compared to mucosal scrapings from non-DSS/AOM treated ERβKO mice (P = 0.042).  
In WT E2 treated mice, the tumors had a 14-fold increase in ERα mRNA expression 
compared to WT E2 normal mucosa (P = 0.015).  In the presence of E2, ERα mRNA 
increased 13-fold in ERβKO adenocarcinomas over ERβKO normal mucosa (P = 0.022). 
 Protein expression levels of ERα were evaluated using immunohistochemistry to 
observe whether or not the mRNA expression levels were representative of protein ERα 
expression (Figure 3.6B-I).  Immunohistochemistry for ERα from tumor sections 
showed strong positive staining for ERα in WT mice with reduced staining levels in 
ERβKO mice both with and without E2 treatment while no staining was evident in the 
normal tissues for either genotype.  
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Figure 3.6.  (A) ERα mRNA expression was evaluated in the tumors and normal colon 
tissue of mice using rtPCR. Values are mean fold change from normal, non-AOM/DSS 
WT-control mice +/- SEM, n=7 in the normal groups, n=4 mice for WT-control, n=4 
mice in the WT-E2 tumor group, n=4 mice in the ERβKO-control group n=2 mice in the 
ERβKO-E2 tumor group.  Bars without a common letter differ, P ≤ 0.0001. B-I, 
Representative photographs of immunohistochemistry for ERα protein in WT-control 
(B-C), WT-E2 (D-E), ERβKO-control (F-G) and ERβKO-E2 (H-I) mice.  For each pair, 
the normal tissue is on the left and the tumor section is on the right.  
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Discussion 
 Studies in both humans and animal models have demonstrated the efficacy for E2 
in protecting against sporadic colon cancer and yet there has been little investigation into 
the influence of E2 on inflammation-associated colon cancer.  Existing data examining 
human populations suggest that the presence of E2 may result in a reduction in the 
occurrence of this disease [111].  Until this point, no animal studies had investigated the 
mechanisms involved in the reduction in inflammation-associated colon cancer 
incidence observed in the presence of E2. Additionally, the exact timing of when E2 can 
be administered and prove protective against colon cancer remains unknown.  Previous 
studies from our laboratory have indicated that E2 guards against early markers of colon 
tumor formation.  As early as hours following carcinogen exposure at the point of initial 
DNA damage, E2 significantly induced apoptosis in the colonic epithelium of rats when 
compared to control animals [160].  In addition, this laboratory has demonstrated that E2 
suppresses the formation of pre-malignant lesions in the colon that was again associated 
with an upregulation of apoptosis in colonic epithelia [63].  
To date, in vivo studies of the protective effects of E2 during the process of colon 
carcinogenesis have only investigated continuous E2 exposure for the duration of the 
studies.  In contrast, the present study aimed to elucidate the chemoprotective role of E2 
when the intervention is given following initiating events in colonic carcinogenesis.  The 
data herein indicates, for the first time, that E2 is protective prior to the formation of 
colon tumors even when administered after DNA and inflammatory damage had 
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occurred in the colon. This protection is characterized by the reduction in tumor 
multiplicity and area. 
 After quantifying fewer colon tumors in response to E2 in this model, I sought to 
determine the physiological responses to E2 at the cellular level and how these reactions 
change over the progression of the disease.  In this study, despite the overall decline of 
tumor number and area, increased proliferation and decreased apoptosis in the 
colonocytes of WT E2 treated tumor bearing animals as compared to cholesterol treated 
controls was observed.  In ERβKO mice, there was no change in proliferation between 
cholesterol and E2 treated animals for either the uninvolved or colon tumor samples. 
When apoptosis was evaluated in the tumors of ERβKO mice, E2 treatment resulted in 
no significant change compared to the cholesterol treated ERβKO mice.  Similarly, data 
from human trials observing the effects of combined estrogen and progestin therapy in 
post-menopausal women show that the combined HRT reduced the incidence of colon 
tumors in these women, however, the tumors that were detected were at a more 
advanced stage [161].  The fact that this similar phenomenon was observed in human 
tissues supports the results detected in the mice in the presented study. While the 
mechanism behind the higher grade tumors was not investigated in the human study, it is 
possible that it could be similar to what was seen in the mice.  
Having observed these counterintuitive responses to E2 in the tumors and 
uninvolved tissues in the mice, a second animal study was conducted to investigate how 
E2 affects normal colonic tissue. In animals that received neither AOM nor DSS, E2 
treatment resulted in no change in proliferation for either WT or ERβKO mice and the 
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non-diseased WT mice had increased apoptosis in the colon.  These data coincide with 
the results observed previously in our laboratory and indicate that the response to E2 may 
be dependent on the stage of the disease and, possibly, the experimental model used in 
this study. 
An intriguing explanation for the surprising response to E2 observed for 
proliferation and apoptosis in the tumor bearing animals could be the changes in ER 
expression detected in this experiment.  Previous studies by this laboratory and others 
have indicated that ERβ, the primary ER within the colon, is the form of the receptor 
through which E2 exerts its protective effects [63, 151].  Other groups have shown that 
ERβKO mice are more susceptible to inflammation-associated colon cancer than WT 
mice [113].  Clinical and experimental models of colon carcinogenesis have suggested 
that protein expression of ERβ decreases as the tissue progresses from normal colonic 
epithelia to a malignant state [87, 88, 162, 163]. In fact, humans with colon tumors not 
expressing ERβ are likely to be in more advanced stages of cancer and have a higher risk 
for death compared to those with tumors in which ERβ is present [89]. In the present 
study, the ERβ expression levels suggest that a similar trend occurs during the formation 
of inflammation-associated colon tumors. Normal colonic tissue had the highest staining 
intensity for ERβ while the tumors had the least, with no changes in ERβ expression due 
to the presence or absence of E2.  Analysis of the uninvolved tissues revealed ERβ 
intensity levels between those of the normal and tumor samples.  The intermediate 
staining intensity of the uninvolved tissues is not surprising when one takes into account 
that while these samples were not cancerous, they were collected from the same colons 
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as the tumors and as such had also sustained high levels of damage and cannot be 
considered normal.  The varying level of ERβ expression between the tissues indicates 
that the loss of expression occurs gradually as inflammation-associated colon tumors 
develop. 
In systems where ERα is the predominantly expressed ER, such as the mammary 
gland, the presence of E2 is often associated with an increase in cancer growth [74, 75, 
164-166].  In normal colon tissue, ERα protein expression is very low, as can be seen by 
the lack of a positive stain in the correlative tissues in this study.  In contrast, 
adenocarcinomas exhibited positive protein staining for ERα and had significantly 
increased ERα mRNA expression: as high as 300-fold over control tissues, supporting 
the idea that ERα activity could be increased in the colon tumors. Contrarily, studies 
conducted utilizing the APCmin/+ mouse model of intestinal carcinogenesis suggest that 
loss of ERα was detrimental to the colon [167, 168].  Disparities observed are likely the 
result of underlying differences between the APCmin/+ mouse model and the 
inflammation protocol used here.   
The possibility of ERα activity exceeding ERβ activity could explain the change 
in physiological response to E2 seen in the tumor bearing mice compared to the non-
diseased mice and to previous studies in this laboratory observing earlier endpoints in 
the process of colon carcinogenesis. It is possible that the protection against colon tumor 
formation in response to E2 observed in this study occurred before ERβ expression 
decreased and ERα expression increased, thus delaying the growth of colon tumors.  
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Once ERα started to be expressed the tumor physiology was altered as indicated by the 
increased proliferation and decreased apoptosis.   
In addition, previous studies from this laboratory suggest that p53 may be a 
primary modulator of the chemoprotective effect of E2 on colon carcinogenesis; non-
malignant Young Adult Mouse Colonocytes (YAMCs) treated in vitro with E2 had 
increased apoptosis and an overall reduction in cell number.  In YAMCs lacking 
functional p53, the effect of E2 was lost [69].  Mutations in p53 occur in roughly 50% of 
colon tumors [169] and the loss of p53 functionality could contribute to the change in 
physiological response to E2 in the tumors in this study.  Due to the timing of tissue 
collection in the presented experiment, analysis of p53 would be inappropriate due to the 
loss of proper p53 function observed in most colon tumors.  Had tissues been harvested 
at an earlier time point following AOM/DSS exposure, it is likely a different response to 
E2 and relevant p53 signaling would have been observed. However, the presented data 
are critical in highlighting the complex role of estrogens in the colon. 
The current study takes a critical step toward understanding the role of E2 in 
colon carcinogenesis.  These data demonstrate that E2 is protective against 
inflammation-associated colon tumor formation, which is important because it is 
estimated that up to 396/100,000 people worldwide suffer from IBD, increasing their 
risk for developing colon cancer [170].  Additionally, E2 protected against the 
development of tumors even when introduced to the system following the initiation of 
inflammation and DNA damage to the colonic tissue.  This observation implies that 
intervention with estrogen therapy may be beneficial in patients considered at high risk 
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for colon cancer even if they have been menopausal for some time. Of utmost interest in 
this study was the observed upregulation of ERα expression with a concurrent reduction 
in ERβ expression.  To my knowledge, this study is the first to definitively demonstrate a 
concurrent and inverse shift in the expressions of ERα and β in any system.  Several 
studies have observed changes in ER expression as the result of treatments or changes in 
disease state.  However, in these studies either only one of the ERs was affected or both 
receptors had either increased or decreased expression [167, 171]. These data provide 
new insight into the role of estrogens in reducing colon tumor formation in patients who 
suffer from colonic inflammation and suggest that intervention can still be successful 
even if begun later in the tumor development process. 
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CHAPTER IV 
ESTRADIOL PROTECTS AGAINST ACUTE TNBS INDUCED 
INFLAMMATION IN THE COLON OF MICE 
 
Introduction 
Inflammatory bowel disease (IBD) affects over one million people in the United 
States.  Typically, IBD occurs in persons in their twenties and thirties at which point 
symptoms lesson for a number of years followed by flare-ups of the disease later in life.  
The two primary forms of IBD, Crohn’s disease and ulcerative colitis, both confer a 
greater lifetime risk for developing colon cancer [101, 102].   This increased risk is most 
likely due to an increased rate of growth and potential mutation of colonocytes due to the 
exposure to pro-inflammatory cytokines.  Interestingly, women have been observed to be 
60% less likely than men to develop inflammation-associated colon cancer, suggesting 
that female hormones may play a role in the prevention of this disease [111]. 
One way that estradiol (E2), the primary form of estrogen in the human body, 
may be protecting against inflammation-associated colon carcinogenesis is through the 
modulation of intestinal inflammation.  Epidemiological studies have observed that pre-
menopausal female patients with Crohn’s disease reported a worsening of their IBD 
related symptoms during menses; the time during the estrous cycle that E2 
concentrations are at their lowest [112].  Not only does this suggest that E2 could be 
protecting against intestinal inflammation, but the fact that the same worsening of 
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symptoms was not observed in women with ulcerative colitis suggests that the role of E2 
in protecting against inflammation could be dependent on the subtype of IBD. 
 Experimental data to support the protective effects of E2 on the development of 
inflammation-associated colon tumors, however, is conflicting.  Data from our 
laboratory indicates that treatment with E2 in mice following induction of inflammation-
associated colon cancer using co-treatment with the colon specific carcinogen 
azoxymethane (AOM) and dextrtan sulfate sodium (DSS) was effective at reducing both 
the number and size of colon tumors [72].  Other groups, however, have observed that in 
mice pre-treated with E2 and then subjected to AOM/DSS, polyp number and size was 
increased [114]. 
 The disparity in the observed results is not limited to the tumor stage.  Studies 
looking at the effects of E2 solely on inflammation have also not reached a consensus. 
Here though, the incongruent findings are likely the result of the models of inflammation 
used.  Studies using DSS as the inflammatory agent found that E2 worsened disease 
severity whereas dinitrobenzene sulfonic acid colitis was improved in the presence of E2 
[114, 115].   Another model of inflammation, 2,4,6-Trinitrobenzenesulfonic acid 
(TNBS) has also been suppressed by estradiol benzoate and the phytoestrogen genistein 
[116, 117].  DSS and TNBS induce inflammation using distinct mechanisms resulting in 
colitis that resembles ulcerative colitis and Crohn’s disease respectively and the 
differential responses to estrogenic compounds to each further suggests that Crohn’s 
disease and ulcerative colitis respond differently to E2. 
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 The focus of the present study is to investigate the physiological actions of E2 
during acute TNBS colitis in wild type and estrogen receptor (ER) β knockout (ERβKO) 
mice.  While previous studies suggest that estrogen is protective against TNBS colitis, 
the mechanism behind this protection is still poorly understood.  Studies in our 
laboratory in both sporadic and inflammation-associated colon cancer suggest that ERβ, 
the primary ER in the colon, mediates the protective effect of E2 in the colon [63, 72]. 
To date, however, the role of ERβ in acute TNBS colitis is unknown.  Understanding the 
role of E2 during acute inflammation is important for developing protective strategies 
against both Crohn’s Disease and inflammation-associated colon cancer.  
 
Methods and Materials 
Animals: C57Bl6/J mice heterozygous for ERβKO (+/-) were originally 
obtained from The Jackson Laboratory.  The mice were housed at the Laboratory 
Animal Resources and Research facility at Texas A&M University.  Mice were bred to 
produce WT and ERβKO offspring and genotype was confirmed using genomic tail 
DNA.  All procedures were performed under a protocol approved by the Institutional 
Animal Care and Use Committee at Texas A&M University. 
Induction of colitis: Female mice were ovariectomized (OVX),  implanted with 
either a 20 mg cholesterol containing pellet or a 0.5 mg E2 + 19.5 mg cholesterol 
(Sigma-Aldrich; St. Louis, MO) pellet and placed on a phytoestrogen free diet.  Two wk 
later they were pre-treated with 1% TNBS dermal absorption through the skin on their 
backs.  One week following pre-treatment, a 2.5% TNBS solution was administered 
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intrarectally 2-4 cm into the colon using a flexible plastic gavage tube (Instech Solomon) 
after a 12 hr fast.  Mice were sacrificed 5 d post intrarectal TNBS.  Colons were resected 
and latitudinaly bisected. One half of the colon was rolled into a Swiss roll and fixed in 
PFA. The other half was snap frozen in liquid nitrogen for cytokine analysis. 
Inflammation and injury in the colons were assessed by a board certified pathologist on 
H&E stained colon Swiss rolls on a scale of 0-3.  In brief, a score of 0 would indicate no 
inflammation or injury noted while a score of 3 would indicate severe inflammation or 
injury.   
Cytokine multiplex analysis:  Snap frozen colon tissues were homogenized in 1 
mL Tissue Protein Extraction Reagent (Thermo Scientific.)  Total protein content was 
assessed using the DC Protein Assay (Bio-Rad) as per the manufacturer’s instructions.  
The Magnetic Mouse Cytokine/Chemokine Milliplex Map Kit was used to measure 
tissue levels of IL-6, IL-10, IL-12(p40), IL-17, GM-CSF, IFNγ, MCP-1, MIP-1α, and 
TNFα following the manufacturer’s instructions.  All samples were diluted to 10 M.  In 
brief, 25 µL diluted sample was added per well of a 96-well plate in addition to 25 µL 
assay buffer and 25 µL of the magnetic beads provided in the kit.  The plate was sealed 
and agitated on a plate shaker overnight at 4°C.  The following day, the 96-well plate 
was placed on a hand-held magnet, the contents of the wells removed, and then the plate 
was washed twice.  Following washing, 25 µL of detection antibodies were added to 
each well and the plate was incubated at room temperature for 1 hr with agitation.  Next, 
25 µL of Streptavidin-Phycoerythrin were added to each well the plate was incubated at 
room temperature for half an hour with agitation.  The plate was then washed twice, the 
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magnetic beads resuspended in 150 µL Luminex Sheath Fluid, and the plate was run on 
a Luminex 200. 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
assay: Paraffin embedded, paraformaldehyde (PFA) fixed colon Swiss-rolls were 
rehydrated and  the ApopTag Peroxidase in situ Apoptosis Detection Kit (Millipore; 
Billerica, MA) was used for the terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labeling (TUNEL) assays following the manufacturer’s instructions with slight 
modifications.  PFA fixed tissues were rehydrated and treated with 10 μg/mL proteinase 
K for 3 min at 37°C.  Endogenous peroxidase activity was blocked using 0.3% H2O2 in 
methanol for 30 min.  Tissues were incubated at room temperature (RT) for 20 sec in 
equilibration buffer and then incubated for 1 hr at 37°C in reaction buffer plus TDT 
enzyme.  The TDT enzyme was omitted from an individual section as a negative control 
for the stain.  Subsequently, slides were placed in stopwash solution for 10 min followed 
by 30 min at RT in anti-digoxigenin in a humidified chamber. A 0.5% DAB solution for 
20 sec was used as the chromagen and nuclei were counter stained in 0.5% methyl green 
for 5 sec.  Lastly, slides were dehydrated and coverslipped. 
Immunohistochemistry for BrdU: Four micrometer sections were taken from 
the PFA fixed tissues.  Sections were deparrafinized and rehydrated.  Endogenous 
peroxidase was quenched using 3% H2O2 in methanol for 30 min and antigen retrieval 
was achieved by microwaving in 10 mM citrate buffer for 20 min.  Slides were then 
incubated in the primary antibody, anti-BrdU (Roche; Basel, Switzerland) diluted 1:20 at 
4⁰C overnight in a humidified chamber.  During each stain, the primary antibody was 
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left off of a single slide to serve as a negative control. The following morning, the slides 
were washed and then incubated in the secondary antibody, goat-anti-mouse-HRP 
(Abcam; Cambridge, MA) diluted 1:250.  Meyer’s haematoxylin was used as the counter 
stain.  Lastly, slides were dehydrated and coverslipped. 
Immunohistochemistry analysis: The TUNEL and BrdU assays were analyzed 
in the same manner.  For each, 20 well oriented crypts per animal from both the distal 
and proximal colon crypts were symmetrically bisected and the right halves of each were 
analyzed.  The total number of positively stained cells was divided by the total number 
of cells in the crypt column to generate the percentage of apoptotic or proliferative cells 
for each column.   
Statistics: Analysis for all data was determined using one-way ANOVA or a 
student t-test Using JMP Pro 10. Differences were considered significant if P<0.05. 
 
Results 
 E2 protects against TNBS induced weight loss and increases colon length:  
All four groups of mice had significant weight loss from their pre-study weights.  WT 
control treated mice lost significantly more weight than WT E2 treated mice.  There was 
no difference in weight loss between ERβKO mice in response to E2 (Figure 4.1A). 
Additionally, E2 treatment increased the length of the colon by approximately 0.5 cm in 
WT but not ERβKO mice (Figure 4.1B).  
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Figure 4.1. (A) Effect of E2  on TNBS Induced Weight Loss. Values  are  mean weight 
loss  per  animal  in grams ± SEM, and (B)  Effect of E2  on Colon Length. Values  are  
mean colon length ± SEM. n = 12 -16 mice per group.  Bars without a common letter 
differ, P ≤ 0.05. 
 
 E2 protects against inflammation and injury in the colon:  After induction of 
acute colitis using TNBS, E2 treated WT mice had reduced inflammation in the middle 
region of the colon. ERβKO mice had reduced inflammation in response to E2 in the 
distal end of the colon (Figure 4.2A).  There were no changes in injury scoring in the 
WT mice for any region of the colon.  The ERβKO E2 treated mice, however, a reduction 
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in injury was observed in the proximal, distal and overall colon compared to ERβKO 
control treated mice (Figure 4.2B).   
   
 
Figure 4.2. Inflammation was induced in the colon of ovariectomized mice with TNBS. 
Sectioned tissues were H&E stained and analyzed by a board certified pathologist. (A) 
Inflammation Scores and (B) Injury Scores. Values are mean score ± SEM. n = 12 - 16 
mice per group.  “*” denotes significance between indicated groups P<0.05. 
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Figure 4.3. Cytokine expression in colon tissue was assessed using a multiplex assay. 
Values are mean expression ± SEM. Bars without a common letter differ, P < 0.05. 
 
 
E2  reduces the expression of pro-inflammatory cytokines:  Cytokine 
expression profiles were determined using a Multiplex magnetic bead assay.  In WT 
mice, treatment with E2 resulted in reduced expression of IL-6, IL-12(p40), IL-17, GM-
CSF, IFNγ, MCP-1, MIP-1α, and TNFα.  In ERβKO mice, IL-6 and TNFα expression 
were significantly down regulated by E2.  Several other cytokines, IL-12(p40), GM-CSF, 
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MCP-1, MIP-1α, and TNFα,  trended towards reduced expression in response to E2 in 
ERβKO mice, however the differences did not reach signifigance (Figure 4.3).    
Proliferation is increased in ERβKO mice: Proliferation was assessed by BrdU 
incorporation into actively dividing cells. Both the proximal and distal ends of the colon 
were analyzed.  The crypts were further divided into bottom, middle and top regions.  
No changes in proliferation were observed in either genotype in response to E2 in the 
proximal colon for any region in the crypt (Figure 4.4A).  In the distal colon, E2 treated 
ERβKO mice had increased proliferation compared to control treated ERβKO mice in 
the bottom third of crypts. No other significant differences were observed in the distal 
colon (Figure 4.4B). 
Apoptosis is decreased in ERβKO mice:  Apoptosis was analyzed in the 
proximal and distal colon using a TUNEL assay. Again, the crypts were divided into 
bottom, middle and top regions to observe changes in the different populations of 
colonocytes.  In the proximal colon, E2 treated ERβKO mice had reduced apoptosis both 
overall and in the top third of colon crypts compared to control ERβKO mice (Figure 
4.5A).  There was a trend for increased apoptosis in E2 treated ERβKO mice in the distal 
colon compared to ERβ controls however no significant changes occurred in the distal 
colon in response to E2 in any region of the crypt for either genotype (Figure 4.5B). 
 76 
 
 
Figure 4.4. Effect of E2  on proliferation during acute inflammation.  Two hours prior to 
sacrifice, mice were injected with 5-bromo-2'-deoxyuridine (BrdU). 
Immunohistochemistry for BrdU was performed on sectioned tissues from the proximal 
and distal colon.  Data are expressed as the percentage of proliferative cells compared to 
the total number of cells for either the full crypt column or the indicated region of the 
crypt.  Data are representative of 20 well-oriented crypts per animal per proximal or 
distal colon with n =12 to 16 mice per group.  (A) Proliferation in the proximal colon 
and (B) Proliferation in the distal colon.  “*” denotes significance between indicated 
groups P<0.05. 
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Figure 4.5. A TUNEL assay was performed on sectioned tissues from the proximal and 
distal colon.  (A) Apoptosis in the proximal colon and (B) apoptosis in the distal colon. 
Data are expressed as the mean percentage of apoptotic cells compared to the total 
number of cells for either the full crypt column or the indicated region of the crypt ± 
SEM.  Data are representative of 20 well-oriented crypts per animal per proximal or 
distal colon with n =12 to 16 mice per group.   “*” denotes significance between 
indicated groups, P<0.05. 
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Discussion 
 Epidemiological studies suggest that E2 is protective against inflammation-
associated colon tumor formation [111].  One mechanism by which this protection may 
occur is through the modulation of acute inflammatory episodes in the colon.  This idea 
is supported by the fact that women with Crohn’s disease report that their IBD 
symptoms worsen during menstruation, when circulating E2 levels are lowest [112].  
Thus far, however, in vivo studies have been inconclusive on the effects of E2 on 
inflammation and inflammation-associated colon cancer.   
 In this study, TNBS was used to mimic acute Crohn’s disease inflammation.  
With this model, E2 treatment was observed to protect against inflammation in WT and 
ERβKO mice in the middle and proximal regions of the colon respectively.  Other 
studies utilizing dextran sulfate sodium (DSS) as the inflammatory reagent that models 
ulcerative colitis have observed that the presence of E2 exacerbates inflammation in the 
colon [114].  Crohn’s disease and ulcerative colitis are physiologically distinct diseases 
and the differences observed in response to the presence of E2 are likely due to the 
inherent differences in the morphology of each disease as well as the models used to 
study them.   
In this study, inflammation was observed to be decreased in the middle and distal 
colon in WT and ERβKO E2 treated mice respectively.  The likely mediator of the 
reduced inflammation is the decreased expression of pro-inflammatory cytokines also 
observed in response to E2. Aberrant expression of cytokines is a hallmark for Crohn’s 
disease, and several of the current treatment therapies are aimed at blocking cytokine 
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activity [172].      Cytokine signaling networks are complicated; involving several cell 
types and multiple positive and negative feedback loops.  In the case of Crohn’s disease, 
antigen presenting cells, such as dendritic cells and macrophages, secrete IL-6, IL-1, IL-
12, IL-18, IL-23, and IL-27 which in turn promote T-cells to secrete more cytokines 
activating macrophages and inducing inflammation [172].  IL-6, IL-12(p40), IFNγ, GM-
CSF, MIP-1α and, TNFα have previously been shown to be upregulated in TNBS 
induced colitis [173].  In WT mice in this study, the 97% reduction in IL-6 could be 
reducing T-cell secretion of IL-17, TNFα, and IFNγ.  The lower TNFα, and IFNγ 
expression would result in decreased macrophage activation, further downregulating IL-
6.  The reduction of T-cell secreted IL-17 would in turn cause expression of IL-6, GM-
CSF, MCP-1 and TNF-α to decrease.   
While cytokine production was also reduced in the ERβKO mice, only 
expression of two of the targets I analyzed, IFNγ and IL-6, was downregulated compared 
to the eight targets affected in the WT mice.  Studies have shown that macrophages 
express ERβ and that ERβ specific agonists can influence cytokine production [174, 
175].  The lack of ERβ in the ERβKO mice could be reducing the ability of these cells to 
respond to E2.    
In immune cells, such as dendritic cells and macrophages, ERα is the 
predominate ER.  Additionally, the spleen and thymus, which are involved in maturing 
immune cells, are ERα expressing tissues [176].  In both the WT and ERβKO mice in 
this study, E2 could be acting through ERα.  Another receptor involved could be the non-
classical ER, G-protein coupled receptor 30 (GPR30). GPR30 has been observed to 
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reduce toll-like receptor 4 (TLR4) expression on macrophages in response to E2 [177]. 
TLR4 binds lipopolysaccharide from Gram-negative bacteria and activates the innate 
immune system and reduction in the expression of this protein could be a method for the 
reduction of inflammation observed in the present study.   
Not only was inflammation reduced by E2, but injury was also mitigated.  For all 
groups, injury scoring was highest in the distal colon, likely a result of the intrarectal 
method of TNBS administration.  The insertion of the gavage tube into the colon 
physically damaged this portion of the tissue.  Due to this fact, the results observed in 
response to E2 in the distal colon in regards to injury are partially reflective of wound 
healing and not solely inflammation.   
E2 treatment was associated with a lower injury score in ERβKO mice in the 
proximal, distal, and overall colon.  The fact that for both inflammation and injury lower 
scores were observed in the presence of E2 suggests that during acute inflammation, ERβ 
is not the primary receptor through which E2 elicits its effects. While ERβ is the primary 
ER in the colon, studies have shown that the colon also expresses ERα.  As opposed to 
ERβ, ERα is associated with increased cell growth. It is possible that E2 binding to ERα 
could be the cause of the increased proliferation in the bottom third of crypts in the distal 
colon of E2 treated ERβKO mice compared to control ERβKO mice.  This increase in 
proliferation may be the underlying mechanism behind the reduction in injury in the 
distal colons of these same mice. By increasing the rate of new cell growth, the ERβKO 
E2 treated mice could be regenerating the tissue that was damaged during TNBS 
administration resulting in a less injured colon.   
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In the proximal colon, the reduction in apoptosis observed in E2 treated ERβKO 
mice compared to control ERβKO mice is likely a downstream effect of the tissues being 
less damaged.  In this instance, E2 may not directly be causing the apoptosis by binding 
to ERs (ERα or otherwise) but rather, due to the lower levels of damaged colonocytes, 
the need for these cells to apoptose to repair the tissue is diminished resulting in the 
reduction in apoptosis.  If this were the case, then the reduction in apoptosis is reflective 
of the protective effect of E2 in the colon. 
The lack of effect on injury in E2 treated WT mice could be due to competitive 
binding for E2 by the different ERs.  If in fact the protection against injury is due to ERα, 
in the WT mice, the ERβ could be tying up the available E2, preventing it from binding 
to ERα.         
Other models of acute colonic inflammation, particularly those utilizing DSS, 
have shown that E2 worsens markers of colonic inflammation.  Heijmans et al. observed 
that WT mice receiving E2 and induced with inflammation using DSS had a higher 
disease activity index, had increased weight loss and significantly increased production 
of the pro-inflammatory cytokine interleukin-6 (IL-6) [114].  Verdú et al also found that 
E2 increased histological inflammatory scores [115].  Contrary to TNBS, DSS induces 
inflammation that models ulcerative colitis. DSS is believed to function via cytotoxicity 
resulting in loss of integrity of the mucosal barrier whereas TNBS is a haptenating 
reagent causing an allergic response from the host in the colon. Studies that have used 
DSS as the inflammatory agent have observed that E2 treated animals do not tolerate 
DSS well and have a poor survival rate compared to controls [114].  This poor tolerance 
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is likely related to the worsening of inflammatory symptoms observed in DSS/E2 
models. 
Structurally similar to E2, phytoestrogens such as genistein are also known to 
bind to ERs.  In other studies using TNBS to induce inflammation, high phytoestrogen 
diets were observed to increase acute colonic colitis.  Seibel et al. observed that rats 
exposed pre-natally and post-natally to diets high in phytoestrogen content had increased 
myeloperoxidase activity, increased colon weights, and ulceration compared to controls, 
all indicative an increase in inflammation [178].   While phytoestrogens often have 
similar effect to E2 in estrogen responsive tissues, this is not always the case.  
Additionally the differences observed between this study and those done with 
phytoestrogens could be due, in part, to changes in the treatment protocol and protocol 
used to induce TNBS colitis.  The rats in the Seibel et al. study were exposed to the 
phytoestrogens from conception onward.  Additionally, the rats in their study did not 
receive a pre-treatment of TNBS [178].   
Overall, data from this study suggest that E2 is protective against acute TNBS 
induced colitis and reduces the expression of pro-inflammatory cytokines in the colon.  
This protective effect is not mediated through ERβ and further investigation will be 
required to determine the molecular mechanism behind the protection observed in the 
presence of E2. These data are an important step towards understanding how E2 protects 
against symptoms of IBD in women with Crohn’s disease and could lead to the 
development of treatment strategies for relieving IBD symptoms in clinical settings.   
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CHAPTER V 
THE EFFECTS OF ESTROGEN RECEPTOR ALPHA AND ESTROGEN 
RECEPTOR BETA IN COLONOCYTES IN VITRO 
   
Introduction 
 The primary estrogen receptor (ER) in the colon is ERβ.  In general, this receptor 
is associated with decreased cell growth and induction of apoptosis.  Studies form our 
laboratory and others have demonstrated that expression of ERβ is requisite for the 
protection against colon tumorgenesis in response to estradiol (E2) the colon for both 
sporadic and inflammation associated models of colon cancer development as well as in 
human studies [63, 72, 167, 179].  As colon tumors develop, it has been observed that 
the expression of ERβ decreases resulting in a loss of effect in response to E2 [87, 88, 
162, 163].    
 The other classical ER in humans is ERα. Contrary to ERβ, ERα is associated 
with an increase in cell division when activated.  In tissues where ERα is the 
predominate ER, E2 is associated with amplified cancer cell growth.  A study from our 
laboratory observed that in addition to the loss of ERβ expression as colon tumors 
developed, ERα expression was upregulated.  This shift in ER expression was 
accompanied by a change in the physiological response to E2 as compared to previous 
studies; apoptosis was downregulated while proliferation was upregulated [72].   
Both ERα and ERβ are nuclear receptors primarily located within the nuclear 
membrane. Upon activation, they dimerize, forming either homo or heterodimers and 
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translocating into the nucleus where they bind to estrogen response elements located 
within the promoter region of target genes.  Once bound, they recruit either co-activators 
or co-repressors to up or downregulate expression of the gene.   
One protein whose expression has been demonstrated to be influenced by E2 in 
vitro is p53.  The p53 protein is a prominent tumor suppressor protein and is known to 
induce cell cycle arrest, apoptosis and DNA repair in response to DNA damage or other 
forms of cellular stress [180, 181].  Loss of heterozygosity of p53 or dominant negative 
mutations to the gene often occur during cancer progression. Mutations to p53 occur in 
over 50% of colon tumors and loss of proper function of the protein is associated with an 
increase in disease severity [169, 182-185].  Studies from our laboratory have observed 
that E2 increases p53 expression levels in non-malignant colonocytes and influences the 
mRNA expression of downstream p53 target genes [69].  In other studies where ERβ is 
expressed in malignant cell lines, such as some breast cancer cell lines and endometrial 
carcinoma cells and osteoblasts, E2 has also been demonstrated to alter expression of p53 
and its downstream targets [186-189].  This upregulation of p53 could, in part, be how 
E2 initiates apoptosis of colonocytes and protects against colon tumor formation. 
The present study aims to elucidate the differing role of ERα and ERβ in non-
malignant colonocytes and a homologous cell line with a mutated p53. By better 
understanding how each of the ERs influence the physiology of colon cells, improved 
strategies for preventing colon cancer in humans may be developed.       
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Materials and Methods 
 Cells: Young adult mouse colonocyte (YAMC) bleo/neo and mp53/neo cells 
were generously provided by Dr. Hartmut Land (University of Rochester Medical 
Center). Cells were cultured in RPMI 1640 (Sigma Aldrich) with 10% fetal bovine 
serum (FBS; HyClone); 0.1% insulin, transferrin, and selenious acid (ITS; BD 
Biosciences); and 1% gentamicin (GIBCO). For general maintenance, cells were placed 
at 33°C with 5 units of γ-interferon (IFNγ) per mL medium (Roche) on rat tail collagen 
type I (BD Biosciences) coated plates. Cells were cultured in media with 2x charcoal-
dextran stripped FBS in place of regular FBS for 72 hr prior to receiving any 
experimental treatments.  During experiments, cells were placed at non-permissive 
conditions; 39°C in the absence of IFNγ.  Treatments, E2, 4,4',4''-(4-Propyl-[1H]-
pyrazole-1,3,5-triyl)trisphenol (PPT, an ERα specific agonist) and diarylpropionitrile 
(DPN, an ERβ specific agonist) (Tocris; Bristol UK) were prepared as 1000x stocks in 
ethanol (EtOH) and delivered as 1 μL/mL medium to achieve the final concentration as 
indicated. 
 Cell number assay: YAMC bleo/neo and mp53/neo cells were seeded at 15,000 
cells per well on six-well plates and grown under non-permissive conditions. Cells were 
treated with vehicle or 1 nM E2, 1, 5 and 10 nM PPT, and 5, 25 and 50 nM DPN as 
indicated for 96 hr. Forty-eight hours after the first treatment, the media was changed 
and treatments were replenished. At the end of the 96-hr treatment period, cells were 
trypsinized and collected for counting. Cell concentration was determined using a 
Beckman Coulter particle counter. Twenty micro-liters of sample were diluted in 10 mL 
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Isotone II diluent (Beckman Coulter). Samples were counted in triplicate. Three wells 
per treatment per experiment were used and three replicate experiments were conducted. 
 ERα transfected cells were counted using the same method following the 
transfection protocol. Treatments were again refreshed after 48 hr with cell number 
being assessed 96 hr post transfection.     
 Apoptosis: YAMC bleo/neo cells (15,000/well) were seeded on 6-well plates 
and grown in stripped serum medium under non-permissive conditions. Cells were 
treated with vehicle or 1 nM E2, 1, 5 and 10 nM PPT, and 5, 25 and 50 nM DPN for 96 
hr. Forty-eight hours after the first treatment, the media and treatments were replaced. At 
the end of the 96-hr treatment period, cells were trypsinized and collected. After 
collection, cells were centrifuged and the medium was replaced with lysis buffer from 
the EnzChek Caspase-3 Assay kit no. 2 (Invitrogen). The Invitrogen protocol was 
followed for this procedure. Fluorescence was measured on a TECAN infinite M200 
plate reader. Three wells per treatment per experiment were used and three replicate 
experiments were conducted. 
 RT-PCR for p53 targets: YAMC bleo/neo and mp53/neo cells (25,000/well) 
were seeded in 6-well plates and maintained under non-permissive conditions in stripped 
serum media. Cells were grown for 72 hr and treated with 1 nM E2 or vehicle for the 
final 18 hr. Cells were trypsinized and centrifuged, and RNA isolation conducted using 
the RNAqueous-4PCR kit (Ambion). 1 μg total RNA was used for cDNA synthesis 
using the Transcriptor First Strand cDNA Synthesis kit (Roche). RT-PCR samples 
contained 9.5 μL FastStart Universal SYBR Green Master Mix (Roche), 1.25 μL 
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forward and reverse primers (18s F-TCA AGA ACG AAA GTC GGA GGT T, 18s R-
GGA CAT CTA AGG GCA TCA CAG, p53 F-AAA GAA AAA ACC ACT TGA TGG 
AGA GT, p53 R-CGG AAC ATC TCG AAG CGT TTA, Bax F-CAC CAG CTC TGA 
GCA GAT G, Bax R-GCG AGG CGG TGA GCA CTC C, Bcl-2 F-ATC TTC TCC 
TTC CAG CCT GA, Bcl-2 R-TCA GTC ATC CAC AGG GCG AT, NOXA F-GAA 
ATG CCT GGT ATT GGA TGG A, NOXA R-GAA CTC AT CCT ATC TCC TTC 
ATC AT, p27 F-GGC CAA CAG AAC AGA AGA AAA TGT, p27 R-GGG CGT CTG 
CTC CAC AGT or PUMA F-GCG GCG GAG ACA AGA AGA, PUMA R-GGA GTC 
CCA TGA AGA GAT TGT ACA; Sigma–Aldrich), 11 μL RNase-free water, and 2 μL 
cDNA. RT-PCR was run on a Bio-Rad iQ5 thermocycler for 45 cycles. 
 Transfection of ERα: Bleo/neo and mp53/neo cells were plated on 12-well 
plates (10,000 cells/well) in stripped-serum media for 72 hr prior to transfections.  Per 
well, 6 µL FuGene 6 (Promega; Madison, WI), 44 µL Opti-MEM (Gibco: Grand Island, 
NY), and 2 µg ERα plasmid. This was incubated at room temperature for 10 min and 
then 2 µL CombiMag (OZ Biosciences; Marseille, France) was added and the mixture 
was incubated 30 more minutes at room temperature.  Next, 50 µL was added to each 
well in 1mL media and the plate was placed on a magnet for 20 min.  Following 
incubation on the magnet, the transfection solution was removed from the cells, fresh 
media was added to the cells and cells were placed at non-permissive conditions.  For 
transfection experiments where treatments were added to the cells, treatments were 
included in the fresh media post-transfection.  
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ERα protein quantification:  Protein was extracted from ERα transfected 
bleo/neo and mp53/neo cells using 50 µL lysis buffer for 30 min at room temperature 0, 
6, 12, 18, and 24 hr post-transfection. Total protein concentrations were determined 
using the DC Protein Assay (Biorad; Hercules, CA) following the manufacturer’s 
instructions.  ERα protein concentration was determined by Western blot using the 
Immobilon Western Chemiluminescent Horseradish Peroxidase Substrate kit 
(Millipore); using the methodology as previously described [190].  Antibodies were 
rabbit-anti-ERα (Santa Cruz Biotechnologies; Santa Cruz, CA), mouse-anti-actin 
(Sigma; St. Louis, MO) and goat-anti-rabbit and goat-anti-mouse IgG (Assay Designs).    
Statistics: Analysis for all data was determined using one-way ANOVA using 
JMP Pro 10. Experiments were run in triplicate. Differences were considered significant 
if P<0.05. 
 
Results 
Functional p53 is required for DPN and E2 to reduce cell number:  Bleo/neo 
and mp53/neo cells were treated with E2 and varying concentrations of PPT and DPN as 
indicated. Cell number was reduced in bleo/neo cells but not mp53/neo cells with E2 and 
the ERβ specific agonist, DPN at all three concentrations.  PPT, an ERα specific agonist, 
had no effect on cell number for either cell line (Figure 5.1). 
DPN and E2 induce apoptosis:  Apoptosis was measured in bleo/neo cells using 
a caspase assay.  Cells treated with both 1 nM E2 and DPN at 50 µM displayed increased 
caspase-3 activity, indicating increased apoptosis for these treatment groups. PPT had no 
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effect on caspase activity at any concentration (Figure 5.2).  Apoptosis was not assessed 
in mp53/neo cells due to the fact that previous studies from our laboratory have observed 
no change in apoptosis in response to E2 in this cell line [69]. 
 
Figure 5.1. Effect of specific agonists on cell number. A cell number assay was 
conducted in (A) bleo/neo and (B) mp53/neo cells in response to E2, DPN, and PPT at 
the concentrations indicated. Bars without a common letter differ, P<0.05. 
 
 
Figure 5.2. Apoptosis in response to E2, DPN, and PPT was measured in bleo/neo cells 
using a caspase-3 assay. Bars without a common letter differ, P<0.05. 
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E2, DPN and PPT all influence expression of p53 and its downstream 
targets: Knowing that apoptosis was induced by both E2 and DPN in bleo/neo cells, I 
next wanted to see whether modulation of the p53 pathway was involved in the 
increased apoptosis.   Expression of the pro-apoptotic downstream targets of p53, 
NOXA, PUMA, BAX, the anti-apoptotic Bcl-2, p27, which is a cell cycle related gene 
and p53 itself were measured using RT-PCR.  Expression of p53 mRNA was increased 
by all three treatment groups.  BAX expression increased 24 and 29 fold over EtOH 
treated controls in response to E2 and DPN respectively. NOXA expression was induced 
by both E2 and PPT, but not DPN. PPT and DPN, but not E2 induced PUMA mRNA 
expression.  Bcl-2 expression was downregulated by both E2 and DPN. No treatment had 
an effect on p27 mRNA expression (Figure 5.3). 
 
Figure 5.3. mRNA expression of p53 and several of its downstream targets was assessed 
using RT-PCR.  (A) Depicts all targets analyzed while (B) has BAX removed from the 
bar graph so changes in the remaining targets are visible. Bars are fold change compared 
to vehicle treated controls for each gene, ± SEM. Bars without a common letter for gene 
target analyzed represent significant differences for that target, P<0.05. 
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ERα overexpression negates the protective effect of E2:  To mimic what was 
observed in vivo [72], ERα was overexpressed in bleo/neo and mp53/neo cells using 
transfection.  In the bleo/neo cells, overexpression of ERα results in a loss of response to 
E2.  No changes in the effect of E2 were observed in the mp53/neo cells.  When ER 
specific agonists were administered to ERα transfected bleo/neo cells, PPT increased cell 
number while DPN reduced cell number (Figure 5.4). 
 
 
Figure 5.4.  Effect of E2 and ER specific agonists on cell number in ERα transfected 
cells. (A) bleo/neo and mp53 cell lines were transfected with ERα and treated with 1 nM 
E2 or EtOH as a control and a cell number assay was performed.  (B) ERα transfected 
bleo/neo cells were treated with 1 nM E2, 10 nM PPT, or 25 nM DPN and a cell number 
assay was conducted. Bars are mean cell number per well of 9 replicate experiments ± 
SEM. Bars without a common letter defer, P<0.05. 
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Discussion 
 The relationship between ERα and ERβ is complex.  Several tissues and systems 
throughout the body express both receptors, including the breast, bone, central nervous 
system and cardiovascular system, and the interplay between the two ERs leads to 
proper tissue function.  Aberrant expression of one ER or the other can occur during the 
development of hormone-related cancers.  For example, in the breast, proper ERα 
expression is lost in roughly 15% of human breast cancers, resulting in resistance to anti-
estrogen therapies in these women [191].  Alternatively, other studies suggest that the 
loss of ERβ expression in breast carcinomas may be the reason behind the loss of 
effectiveness of anti-estrogen effectiveness at treating the disease.  This loss of ERβ 
expression is thought to be due to hypermethylation of the promoter region of the gene 
[192-194].   
 In colon cancer, expression of ERβ has been shown to decrease as colon tumors 
develop both in vivo and in human studies [87, 88, 162, 163].  A study from our 
laboratory has demonstrated that in addition to the loss of ERβ, during inflammation-
associated colon tumorgenesis ERα expression concomitantly increases.  In the present 
study, I use an in vitro colon cell model, specific ER agonists and transfection of ERα to 
better understand the differing actions and physiological roles or ERα and ERβ in the 
colon. 
 When a cell number assay was performed in both non-malignant mouse 
colonocytes, YAMC bleo/neos, and in a homologous cell line with a mutated p53, 
YAMC mp53/neos, cell number was observed to decrease in the bleo/neos in response to 
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both E2 and the ERβ specific agonist DPN, but not in response to the ERα specific 
agonist PPT. This suggests that, as had been previously proposed, ERβ is the primary ER 
through which E2 exerts its protective effect in colonocytes.  These same treatments in 
the mp53/neos had no effect, indicating that a functional p53 is requisite for the 
protection observed with E2. 
 Related to p53, which is an important tumor-suppressor gene known to initiate 
cell cycle arrest, apoptosis, and DNA repair, I next measured induction of apoptosis in 
the bleo/neo cells.   Both 1 nM E2 and 50 nM DPN significantly induced apoptosis as 
measured by caspase-3 activity. Interestingly, analysis of the mRNA expression of 
downstream p53 targets revealed that all three agonists influenced the expression of the 
targets despite only E2 and DPN resulting in quantifiable changes in apoptosis and cell 
number.  
YAMC bleo/neo cells have been observed to express both ERα and ERβ at the 
mRNA and protein level [69]. Therefore, it is feasible that PPT binding to the receptor 
could be influencing p53 targets.  The fact that no changes in cell number and apoptosis 
were observed in response to PPT in the bleo/neo cells suggests that perhaps the 
upregulated pro-apoptotic mRNA transcripts are not being translated into protein. 
Alternatively, the PPT could also be instigating pro-proliferative pathways that could 
counteract any changes in apoptosis resulting in the lack of change in cell number. 
Further investigation is required to understand the function of ERα as it relates to these 
genes in the colon. 
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Once I knew the roles of ERα and ERβ in the bleo/neo and mp53/neo cells with 
endogenous ER expression levels, I next wanted to mimic what I had observed in the 
inflammation-associated colon tumor development where ERα expression was 
increased.  ERα was overexpressed in bleo/neo and mp53/neo cells using transfection.  
The higher levels of ERα protein in bleo/neos abrogated the protective effect of E2.  
Using the specific ER agonists in the transfected cells revealed that the lack of change in 
cell number in these cells was due to the effects of ERα and ERβ canceling each other 
out; DPN reduced ERα overexpressed bleo/neo cell number while PPT increased cell 
number.  The fact that DPN effectively reduced cell number even when ERα was 
overexpressed suggests that ligands specific to ERβ could be a possible treatment option 
for colon tumors that still express some ERβ. 
In the mp53/neo cells, ERα overexpression had no effect on the lack of response 
to the cells to E2 in regards to cell number.  Further study is required in this cell line 
when transfected with ERα to observe the individual effect of ERα and ERβ specific 
ligands.  Additionally, experiments knocking down ERβ expression will need to be 
conducted to further understand how loss of this ERs expression affects the physiology 
of colonocytes. 
    While additional experiments are needed to continue to explore the dynamic 
between ERα and ERβ as inflammation-associated colon tumors develop, the data 
presented in this study are critical towards understanding the roles of these receptors in 
colonocytes.  By understanding how these receptors function in colonocytes, improved 
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strategies for preventing and treating colon cancer may be developed, be it through the 
use of ER specific agonists or other means. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 
 Previous studies investigating the role of E2 during colon cancer development 
suggest that E2 is chemoprotective as opposed to chemotherapeutic.  Malignantly 
transformed cell lines, in most cases, are non-responsive to treatment with E2 [66-68].  In 
non-malignant colonocytes, however, E2 treatment is associated with a decrease in cell 
number and increase in apoptosis via a p53 dependent mechanism [69].   The studies 
presented herein demonstrate the protective effect of E2 early during both sporadic and 
inflammation-associated colon cancer models. Specifically, the actions of E2 were first 
investigated during the initiation stage of carcinogenesis as measured by DNA adduct 
formation. Secondly, the effectiveness of E2 at preventing inflammation-associated colon 
tumor formation was assessed when administered following the initiation of DNA 
damage and induction of colitis.  The final in vivo experiment focused on E2 and acute 
inflammation in the colon in the absence of carcinogen. Lastly, in vitro studies were 
conducted to explore the differing roles or ERα and ERβ in colonocytes. 
In the in vivo model of sporadic colon carcinogenesis, E2 was observed to induce 
apoptosis following the initiation of DNA damage in the colon using the colon specific 
carcinogen, AOM. Also in this model, dietary fish oil was equally effective at reducing 
DNA adduct formation in the presence and absence of E2. E2 itself, however, had no 
effect on DNA adduct formation.  Data from this study suggest that induction of 
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apoptosis in DNA damaged colonocytes could be a primary mechanism for the 
protection against eventual colon tumor formation. 
E2 was also determined to be protective against inflammation-associated colon 
tumor development. Here, colon tumor number and size were decreased, however, 
further analysis of the tumors indicated that apoptosis was downregulated and 
proliferation upregulated. This lead to perhaps most interesting data from this 
experiment: a concurrent decrease in ERβ with an increase in ERα.  The shift in ER 
expression is likely the cause for the altered response to E2 in regards to proliferation and 
apoptosis and was further explored in vitro.  
The in vitro experiments further expounded on the function of ERα and ERβ in 
colonocytes.  ERβ was observed to be the receptor through which E2 exerted its 
protective effect, as seen by induction of apoptosis and a decrease in cell number in 
response to an ERβ specific agonist, DPN.  Similar to what was witnessed in vivo, ERα 
overexpression abrogated the protective effect of E2 on reducing cell number.  
Additionally, in vitro experiments found that the protective effects of E2 and DPN are 
dependent on functional p53. 
Also related to the inflammation-associated colon cancer study, a separate in vivo 
study was conducted investigating the effects of E2 on acute inflammation in the colon.  
In this study, E2 protected against both inflammation and injury in the colon via a non-
ERβ dependent mechanism.  Apoptosis was reduced and proliferation increased in E2 
treated ERβKO mice, likely a downstream effect of the protection against injury also 
observed in these mice. 
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Collectively, these studies suggest that E2 is protective against both sporadic and 
inflammation-associated colon cancer development, primarily during the early stages of 
carcinogenesis.  Additionally, ERα and ERβ were determined to have physiologically 
distinct actions in the colon.  In regards to ERβ, which is widely considered to be the 
primary ER in the colon, its expression was found to be requisite for the protection seen 
during inflammation-associated colon tumor formation.  For acute inflammation, 
however, the protection conferred by the presence of E2 was not dependent on ERβ and 
in fact, the majority of the protective effects were observed in mice lacking ERβ.  The 
information learned through these studies highlight the complex actions of E2 in the 
colon and provide insight into developing future preventative strategies against 
inflammation and colon cancer.   
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